Out of 11729 trials submitting AE data on 8,960,997 participants,

381 trials (n=1,329,598 patients - so they were big trials) reported at least one hypoventilation event. 1018 trials (n=2286075) reported events possibly caused by resp dep.

A total of 815 (!!!) hypercap/hypoventilation events were recorded. So rare…

A total of 3539 possible hypercap/hypovent events were reported.

Note: here are the terms used as well as their frequencies:

Definitive:

ae\_name Freq. Percent Cum.

respiratory acidosis 138 23.55 23.55

hypercapnia 123 20.99 44.54

apnoea 102 17.41 61.95

respiratory depression 78 13.31 75.26

hypoventilation 48 8.19 83.45

apnea 32 5.46 88.91

respiratory insufficiency 14 2.39 91.30

hypercapnic coma 10 1.71 93.00

neonatal respiratory depression 6 1.02 94.03

hypercapnic encephalopathy 5 0.85 94.88

respiratory muscle weakness 3 0.51 95.39

apnea/respiratory distress 2 0.34 95.73

apnoea neonatal 2 0.34 96.08

dyapnoea 2 0.34 96.42

hypopnoea 2 0.34 96.76

infantile apnoea 2 0.34 97.10

neonatal respiratory acidosis 2 0.34 97.44

acute on chronic respiratory insuffic.. 1 0.17 97.61

apnea or respiratory arrest 1 0.17 97.78

central-alveolar hypoventilation 1 0.17 97.95

depressed respiration 1 0.17 98.12

hyopercapnic coma 1 0.17 98.29

hypercapnic respiratory failure 1 0.17 98.46

hypercarbia 1 0.17 98.63

hypercarbic respiratory failure 1 0.17 98.81

hypoxia and respiratory insufficiency 1 0.17 98.98

hypoxia due to hypoventilation due to.. 1 0.17 99.15

infantile apnea 1 0.17 99.32

neonatal respiratory depression \* 1 0.17 99.49

pneumonia and type 2 respiratory fail.. 1 0.17 99.66

severe respiratory acidosis 1 0.17 99.83

type 2 respiratory failure 1 0.17 100.00

Total 586 100.00

Possible:

ae\_name Freq. Percent Cum.

cardio-respiratory arrest 1,171 65.97 65.97

respiratory arrest 393 22.14 88.11

chronic respiratory failure 166 9.35 97.46

cardiorespiratory arrest 12 0.68 98.14

cardio respiratory arrest 8 0.45 98.59

cardio-respiratory arrest neonatal 3 0.17 98.76

dependence on respirator 3 0.17 98.93

respiratory failure -copd 3 0.17 99.10

acute and chronic respiratory failure.. 2 0.11 99.21

failure respiratory 2 0.11 99.32

respiratory failure -other 2 0.11 99.44

acute on chronic respiratory failure 1 0.06 99.49

acute repiratory failure 1 0.06 99.55

apnea or respiratory arrest 1 0.06 99.61

bradycardia and atrial flutter with h.. 1 0.06 99.66

cardiac respiratory arrest 1 0.06 99.72

cario-respiratory arrest 1 0.06 99.77

chronic respitory failure 1 0.06 99.83

dependence on ventilator 1 0.06 99.89

neonatal respiratory arrest 1 0.06 99.94

respiratory status compromised 1 0.06 100.00

Total 1,775 100.00

Here is a list of all the arms that reported 1 or more hypoventilation/hypercap events

Placebo 62 12.60 12.60

Darbepoetin Alfa 4 0.81 13.41

Control 3 0.61 14.02

All Patients 2 0.41 14.43

Cinacalcet 2 0.41 14.84

Control Group 2 0.41 15.24

Denosumab 120 mg Q4W 2 0.41 15.65

Enoxaparin 2 0.41 16.06

Linezolid 2 0.41 16.46

Palivizumab 2 0.41 16.87

Sufentanil NanoTab PCA System/15 mcg 2 0.41 17.28

Usual Care 2 0.41 17.68

Vadadustat 2 0.41 18.09

Vancomycin 2 0.41 18.50

"Rescue" Course of Betamethasone or D.. 1 0.20 18.70

10 MG/KG IPILIMUMAB + PLATINUM/ETOPOS.. 1 0.20 18.90

10 mg Empagliflozin 1 0.20 19.11

100% Maltodextrin 1 0.20 19.31

10PP-LD/Infanrix Hexa Group 1 0.20 19.51

13vPnC Post-Infant Series 1 0.20 19.72

20 mg/kg/Day GWP42003-P 1 0.20 19.92

7vPnC Infant Series 1 0.20 20.12

A - Capecitabine + Enzastaurin 1 0.20 20.33

A-Intervention 1 0.20 20.53

A: Faricimab 6 mg Q8W 1 0.20 20.73

AMR101 1 0.20 20.93

ARM A (ZDV Alone) 1 0.20 21.14

ART-123 1 0.20 21.34

ATLANTIS Cervical Plate System 1 0.20 21.54

ATV/r + FTC/TDF 1 0.20 21.75

AVP-923-20 (Double-blind) 1 0.20 21.95

Abatacept (Long-term Period) 1 0.20 22.15

Aclidinium 400 Î¼g 1 0.20 22.36

Aclidinium Bromide 1 0.20 22.56

Afatinib Monotherapy (Part A) 1 0.20 22.76

Aflibercept 2 mg 1 0.20 22.97

Albaconazole 400 mg (24 Weeks) Oral W.. 1 0.20 23.17

Albumin 1 0.20 23.37

Alectinib 600 mg (Fed): Phase II 1 0.20 23.58

Alirocumab 1 0.20 23.78

Aliskiren 1 0.20 23.98

All Participants 1 0.20 24.19

All Tofacitinib 1 0.20 24.39

Ambrisentan 1 0.20 24.59

Ambrisentan Monotherapy 1 0.20 24.80

Anastrozole 1 0.20 25.00

Anti-ST2 1 0.20 25.20

Any Secukinumab 300 mg 1 0.20 25.41

Any Secukuinumab 300 mg (2x1mL PFS) 1 0.20 25.61

Apixaban, 2.5 mg BID + Placebo 1 0.20 25.81

Apixiban, 2.5 mg BID Plus Placebo 1 0.20 26.02

Aprepitant Regimen 1 0.20 26.22

Arm 2: Methylprednisolone 1 0.20 26.42

Arm 2A (PPV-23) 1 0.20 26.63

Arm 2B (PCV-10) 1 0.20 26.83

Arm A (Paclitaxel + Carboplatin + Rad.. 1 0.20 27.03

Arm A: Continuous Letrozole 1 0.20 27.24

Arm B (Paclitaxel + Carboplatin + Rad.. 1 0.20 27.44

Arm B: Anastrozol - 1 mg Per Day for .. 1 0.20 27.64

Arm C (Safety/ Dose Level 1) 1 0.20 27.85

Arm D (Bevacizumab Cycles 9-18 of Arm.. 1 0.20 28.05

Arm III (Paclitaxel for 4 Courses) 1 0.20 28.25

Arm IV (Paclitaxel for 6 Courses [Clo.. 1 0.20 28.46

Asfotase Alfa 1 0.20 28.66

Aspirin + Extended Release Dipyridamo.. 1 0.20 28.86

Atezolizumab + Enzalutamide 1 0.20 29.07

Azithromycin 1 0.20 29.27

B: Faricimab 6 mg PTI 1 0.20 29.47

BGF MDI 320/14.4/9.6 Î¼g 1 0.20 29.67

BIIB092 Early Start (Open-label Exten.. 1 0.20 29.88

BMS-986036 20 mg 1 0.20 30.08

BMS-986231 - Part I 1 0.20 30.28

BPC-NOLC: Placebo Only 1 0.20 30.49

Benra 10 mg 1 0.20 30.69

Benralizumab 30 mg 1 0.20 30.89

Bevacizumab + Chemotherapy 1 0.20 31.10

Blinded Phase: SIM 200 mg 1 0.20 31.30

Bosentan 1 0.20 31.50

Bucindolol Hydrochloride 1 0.20 31.71

C2 (Indacaterol/@Glycopyrronium) 1 0.20 31.91

CNI Continuation in Stable Renal Tran.. 1 0.20 32.11

COAPT CAS Group 1 0.20 32.32

CP-751,871 + Exemestane 1 0.20 32.52

Canagliflozin (Experimental) 1 0.20 32.72

Canagliflozin 100 mg 1 0.20 32.93

Canagliflozin 100 mg: Baseline to Wee.. 1 0.20 33.13

Carboplatin Plus Paclitaxel 172-225 m.. 1 0.20 33.33

Carfilzomib 1 0.20 33.54

Caspofungin 1 0.20 33.74

Caspofungin 70/50 mg 1 0.20 33.94

Catheterized Cohort 1 0.20 34.15

Cervidil 10 mg Vaginal Insert 1 0.20 34.35

Cetuximab 250 mg/m^2 q1w + Platinum-b.. 1 0.20 34.55

Cetuximab Plus Chemotherapy 1 0.20 34.76

Chemotherapy Alone 1 0.20 34.96

Clofarabine+Cytarabine 1 0.20 35.16

Clopidogrel 1 0.20 35.37

Clopidogrel + ASA 1 0.20 35.57

Clopidogrel / Placebo 1 0.20 35.77

Clopidogrel 600/150/75 mg + ASA High .. 1 0.20 35.98

Cohort 1-Bupivacaine HCl 1 0.20 36.18

Combination of Aliskiren and Enalapril 1 0.20 36.38

Combivent Respimat 1 0.20 36.59

Control Group-Infant 1 0.20 36.79

Conventional Low-Risk Patients 1 0.20 36.99

CoreValve TAVR System - Randomized 1 0.20 37.20

Ctrl2+1-6W-6M/053 Group 1 0.20 37.40

Cytarabine+Daunorubicin+Etoposide 1 0.20 37.60

DB: Denosumab 1 0.20 37.80

DR-ICD/CRT-D 1 0.20 38.01

DRV/Rtv 800/100 mg Once Daily 1 0.20 38.21

Dabigatran 110 mg 1 0.20 38.41

Dabigatran 150 mg 1 0.20 38.62

Dabigatran 150mg 1 0.20 38.82

Dabrafenib + Placebo 1 0.20 39.02

Dalcetrapib 1 0.20 39.23

Dapa 10 mg 1 0.20 39.43

Daprodustat 1 0.20 39.63

Darapladib 160 mg 1 0.20 39.84

Depodur Group 1 0.20 40.04

Desmoteplase 1 0.20 40.24

Device 1 0.20 40.45

Dexpramipexole 1 0.20 40.65

Diet-Limited 1 0.20 40.85

Dinoprostone Vaginal Insert (DVI) 1 0.20 41.06

Double-Blind Atrasentan 1 0.20 41.26

Double-blind BTDS 5 1 0.20 41.46

Double-blind Period: Alendronate 70 m.. 1 0.20 41.67

Double-blind Treatment: Placebo 1 0.20 41.87

Double-blind, Placebo-controlled: Gro.. 1 0.20 42.07

Dulaglutide 1 0.20 42.28

Dupilumab 300 mg q2w 1 0.20 42.48

Durvalumab 1 0.20 42.68

Durvalumab + Tremelimumab 1 0.20 42.89

Dutasteride 0.5 mg 1 0.20 43.09

E+OFS 1 0.20 43.29

E-Ld Cohort 1 0.20 43.50

Early Start Treatment 1 0.20 43.70

Ecallantide 1 0.20 43.90

Edoxaban 1 0.20 44.11

Efficacy Phase 1 0.20 44.31

Endovascular 1 0.20 44.51

Endovascular Repair 1 0.20 44.72

Engerix-B 1 0.20 44.92

Epanova 1 0.20 45.12

Epoetin Alfa:Once Weekly (QW) 1 0.20 45.33

Esomeprazole 1 0.20 45.53

Etoricoxib 90 mg 1 0.20 45.73

Evacetrapib 1 0.20 45.93

Evolocumab 1 0.20 46.14

Exemestane 1 0.20 46.34

Extension Phase: Lemborexant 10 mg 1 0.20 46.54

FF/UMEC/VI 100/62.5/25 1 0.20 46.75

FF/VI 100/25 1 0.20 46.95

FF/VI 100/25 + UMEC 62.5 1 0.20 47.15

FIRMAGON 1 0.20 47.36

Fibrocaps + Gelatin Sponge 1 0.20 47.56

Fluticasone Furoate 100 Âµg 1 0.20 47.76

Fluticasone Maintenance 1 0.20 47.97

Fluticasone Withdrawal 1 0.20 48.17

GFF MDI 14.4/9.6 Î¼g 1 0.20 48.37

GSK1437173A Group 1 0.20 48.58

GSK1572932 Group 1 0.20 48.78

GSK257049 [5-17M] Group 1 0.20 48.98

GWP42003-P 10 mg/kg/Day Dose-Safety A.. 1 0.20 49.19

GWP42003-P 20 mg/kg/Day Dose 1 0.20 49.39

Gelatin Sponge 1 0.20 49.59

Gemcitabine 1 0.20 49.80

Gimsilumab 1 0.20 50.00

Glatiramer Acetate 40mg 1 0.20 50.20

Glimepiride 1 0.20 50.41

GnRH Agonist 1 0.20 50.61

Group 1 1 0.20 50.81

Group 1 - Ravulizumab + BSC 1 0.20 51.02

Group 2 - BSC Alone 1 0.20 51.22

Group 2 - Placebo (Normal Saline (NaC.. 1 0.20 51.42

Group 2-SR-avg ALL, Arm II-combinatio.. 1 0.20 51.63

Group II 1 0.20 51.83

HCRI DAPT - BMS 12-month DAPT 1 0.20 52.03

Hb-Based Titration Group 1 0.20 52.24

High Dose Acetaminophen 1 0.20 52.44

High Dose Edoxaban/Placebo Warfarin 1 0.20 52.64

High Dose Pantoprazole (1.2 mg/kg) 1 0.20 52.85

High-Risk Group 1 0.20 53.05

HydroCoil Embolic System 1 0.20 53.25

IAI 2 mg Groups Combined (2Q16 & 2Q8) 1 0.20 53.46

IM Midazolam 1 0.20 53.66

IMI/REL 1 0.20 53.86

IRBESARTAN 1 0.20 54.07

IV Isotonic Bicarbonate & Oral N-acet.. 1 0.20 54.27

IV Isotonic Saline & Oral Placebo 1 0.20 54.47

IV Lorazepam 1 0.20 54.67

IV Only 1 0.20 54.88

Imipenem-cilastatin 1 0.20 55.08

Infant Participants: Placebo 1 0.20 55.28

Infant Participants: RSVpreF 240 mcg .. 1 0.20 55.49

Infant, (Mother Received Triple ARV (.. 1 0.20 55.69

Infant, (Mother Received ZDV+sdNVP+TR.. 1 0.20 55.89

Infants of Mothers in Arm 1A (PPV-23) 1 0.20 56.10

Intravitreal Aflibercept Injection (I.. 1 0.20 56.30

Intubated With Propofol (IP) 1 0.20 56.50

Inv\_MMR\_Med Group 1 0.20 56.71

Investigational 1 0.20 56.91

Investigators Choice of Chemotherapy .. 1 0.20 57.11

Ipilimumab Plus gp100 1 0.20 57.32

Isavuconazole 1 0.20 57.52

Ivabradine 1 0.20 57.72

Ixabepilone, 40 mg/m^2, Intravenously.. 1 0.20 57.93

K-877: 12-Week Efficacy 1 0.20 58.13

LCZ696 1 0.20 58.33

LCZ696 (Sacubitril/Valsartan) 1 0.20 58.54

Lanreotide AutogelÂ® 120 mg - All Sub.. 1 0.20 58.74

Laser 1 0.20 58.94

Laser Photocoagulation 1 0.20 59.15

Late Epoetin Beta Therapy 1 0.20 59.35

Left Atrial Ablation 1 0.20 59.55

Levodopa-Carbidopa Intestinal Gel 1 0.20 59.76

Levosimendan 1 0.20 59.96

Linagliptin 1 0.20 60.16

Liraglutide 1 0.20 60.37

Long Acting B2 Agonist (LABA) and Inh.. 1 0.20 60.57

Lorcaserin 10 mg 1 0.20 60.77

Losartan 150 mg 1 0.20 60.98

Losartan 50 mg 1 0.20 61.18

Losmapimod 7.5 mg BID 1 0.20 61.38

Lotus Valve System - Randomized 1 0.20 61.59

Low GR270773 1 0.20 61.79

MEDI8897 50 mg 1 0.20 61.99

MP-376 240 mg BID 1 0.20 62.20

Matching Placebo 1 0.20 62.40

MenACWY-CRM 1 0.20 62.60

Menhibrix Group 1 0.20 62.80

Mepolizumab 100 mg SC 1 0.20 63.01

Methotrexate 1 0.20 63.21

Methoxy Polyethylene Glycol-Epoetin B.. 1 0.20 63.41

Misoprostol Vaginal Insert (MVI) 100 1 0.20 63.62

Misoprostol Vaginal Insert (MVI) 50 1 0.20 63.82

MitraClip System 1 0.20 64.02

Mitral Valve Repair 1 0.20 64.23

Monotherapy ARB 1 0.20 64.43

Motavizumab 1 0.20 64.63

Motavizumab (MEDI-524) 1 0.20 64.84

Moxifloxacin (Avelox, BAY12-8039) 1 0.20 65.04

Multi-drug Regimen 1 0.20 65.24

Mupirocin (Treatment) 1 0.20 65.45

Mycobutin (Rifabutin) 1 0.20 65.65

Naproxen 1 0.20 65.85

Native Airway - no Intubation 1 0.20 66.06

Navarixin 10 mg 1 0.20 66.26

Neem Mouthrinse 1 0.20 66.46

Nifurtimox 60 Days / Arm 1 1 0.20 66.67

Nintedanib + mFolfox6 1 0.20 66.87

Non-Surgical Management 1 0.20 67.07

Non-randomized Arm 1 0.20 67.28

Nusinersen 1 0.20 67.48

Olesoxime 1 0.20 67.68

Olo 10 mcg 1 0.20 67.89

Omecamtiv Mecarbil 1 0.20 68.09

Open Repair 1 0.20 68.29

Open-Label Treatment (Placebo) 1 0.20 68.50

Open-label CR845 0.5 mcg/kg 1 0.20 68.70

Open-label Fondaparinux 2.5 mg 1 0.20 68.90

Open-label Period: Avalglucosidase Alfa 1 0.20 69.11

Open-label lead-in Treatment: Tirasem.. 1 0.20 69.31

Overall Study: Alendronate / Alendron.. 1 0.20 69.51

Ozanezumab IV 1 0.20 69.72

PAP: Avalglucosidase Alfa 1 0.20 69.92

PCI-32765 1 0.20 70.12

PF-04950615 100 mg: Every 14 Days 1 0.20 70.33

PLACEBO 1 0.20 70.53

Paclitaxel/Carboplatin Induction 1 0.20 70.73

Palonosetron and Placebo to Ondansetron 1 0.20 70.93

Panitumumab 1 0.20 71.14

Part 1: Molnupiravir 400 mg 1 0.20 71.34

Part 1: Otilimab 90 mg 1 0.20 71.54

Part 1: Placebo 1 1 0.20 71.75

Part 2: Molnupiravir 1 0.20 71.95

Part 2: Placebo 1 0.20 72.15

Part B: IV Sildenafil 1 0.20 72.36

Part B: Placebo Matched to Suptavumab 1 0.20 72.56

Part B: Remdesivir for 10 Days (Exten.. 1 0.20 72.76

Part B: Remdesivir for 10 Days (Mecha.. 1 0.20 72.97

Part B: Suptavumab 30 mg/kg - 2 Doses 1 0.20 73.17

Part B: Suptavumab 30 mg/kg- 1 Dose 1 0.20 73.37

Pegilodecakin + FOLFOX 1 0.20 73.58

Peginesatide 1 0.20 73.78

Pemetrexed 1 0.20 73.98

Phase 2 Arm C-T10 mg/kg (Q4W) 1 0.20 74.19

Phase 2: Placebo 1 0.20 74.39

Phase 2: Sarilumab 200mg IV 1 0.20 74.59

Phase 3 Cohort 1: Sarilumab 200 mg IV.. 1 0.20 74.80

Phase 3 Cohort 1: Sarilumab 400 mg IV.. 1 0.20 75.00

Phase 3 Cohort 1: Sarilumab 400mg IV .. 1 0.20 75.20

Phase 3 Cohort 2: Placebo 1 0.20 75.41

Physical Activity 1 0.20 75.61

Pirfenidone+Sildenafil 1 0.20 75.81

Pitocin 1 0.20 76.02

Placebo (5% Dextrose) 1 0.20 76.22

Placebo (Normal Saline) 1 0.20 76.42

Placebo (Placebo) 1 0.20 76.63

Placebo + Carboplatin + Etoposide 1 0.20 76.83

Placebo + Paclitaxel/ Carboplatin 1 0.20 77.03

Placebo + SOC 1 0.20 77.24

Placebo + Simvastatin 1 0.20 77.44

Placebo - Part A 1 0.20 77.64

Placebo BID 1 0.20 77.85

Placebo Comparator 1 0.20 78.05

Placebo Plus Docetaxel 1 0.20 78.25

Placebo for Levosimendan 1 0.20 78.46

Placebo, Blunt Trauma 1 0.20 78.66

Placebo-HM 1 0.20 78.86

Placebo-No Postoperative Treatment 1 0.20 79.07

Placebo-STM 1 0.20 79.27

Placebo/Sitagliptin: Baseline to Week.. 1 0.20 79.47

Placebo/Sitagliptin: Baseline to Week.. 1 0.20 79.67

Placebo: Conventional Liquid Bicarbon.. 1 0.20 79.88

Plates 1 0.20 80.08

Prasugrel 1 0.20 80.28

Pre-Frail-HZ/su 1 0.20 80.49

Prevenaâ¢ Incision Management System 1 0.20 80.69

Primary PCI (Group B) 1 0.20 80.89

QVA149 1 0.20 81.10

ROSUVASTATIN 20 MG 1 0.20 81.30

RSG in Addition to Background MET 1 0.20 81.50

Ramipril (ONTARGET) 1 0.20 81.71

Randomized Sibutramine 1 0.20 81.91

Ranibizumab 0.1 mg 1 0.20 82.11

Rate or Rhythm Control Therapy 1 0.20 82.32

Regimen 2 - 2MHRZ/2MHR 1 0.20 82.52

Regimen 2 Conivaptan BID 1 0.20 82.72

Regimen B 1 0.20 82.93

Remdesivir + Placebo (RDV+PBO) 1 0.20 83.13

Rivaroxaban (Xarelto, BAY59-7939) 1 0.20 83.33

Rivaroxaban 10 mg Once Daily (OD) (Xa.. 1 0.20 83.54

Rivaroxaban Placebo + Aspirin 100mg 1 0.20 83.74

Roflumilast 1 0.20 83.94

RotaTeqâ¢ 1 0.20 84.15

Routine Vaccines 1 0.20 84.35

Routine Vaccines (All) 1 0.20 84.55

Ruboxistaurin 1 0.20 84.76

Ruxolitinib 1 0.20 84.96

SRL Conversion in Stable Renal Transp.. 1 0.20 85.16

SUN13837 1 0.20 85.37

SURFAXIN High Dose 1 0.20 85.57

SURFAXIN Low Dose 1 0.20 85.77

Saline 1 0.20 85.98

Salmeterol 1 0.20 86.18

Satralizumab, DB Period 1 0.20 86.38

Serelaxin + Standard of Care 1 0.20 86.59

Sham Treatment (Baseline to Week 24) 1 0.20 86.79

Shorter-storage Red Blood Cell Units 1 0.20 86.99

Simvastatin 1 0.20 87.20

Siponimod (BAF312) 1 0.20 87.40

Sitagliptin 100 mg 1 0.20 87.60

Sitagliptin 100mg (Drug Naive) 1 0.20 87.80

Solifenacin 5 mg + Mirabegron 25 mg 1 0.20 88.01

Sorafenib 1 0.20 88.21

Sorafenib (Nexavar, BAY43-9006) 1 0.20 88.41

Standard Cannula 1 0.20 88.62

Standard Medical Treatment 1 0.20 88.82

Standard of Care (SOC) 1 0.20 89.02

Staphylococcus Aureus 4-antigen (SA4Ag) 1 0.20 89.23

Sufentanil NanoTab 10 Mcg 1 0.20 89.43

Sustained 1 0.20 89.63

Synflorix/Infanrix Hexa Group 1 0.20 89.84

T+OFS 1 0.20 90.04

TAS-114 + S-1 1 0.20 90.24

TMC435 150mg 12Wks PR24/48 1 0.20 90.45

TNFi 1 0.20 90.65

Tamoxifen 1 0.20 90.85

Telavancin 1 0.20 91.06

Telcagepant 140 mg 1 0.20 91.26

Telmisartan (ONTARGET) 1 0.20 91.46

Telmisartan/Ramipril (ONTARGET) 1 0.20 91.67

Therapeutic Hypothermia 1 0.20 91.87

Therapeutic Normothermia 1 0.20 92.07

Tio+Olo FDC (5/5 Î¼g) 1 0.20 92.28

Tiotropium (2.5 Î¼g) 1 0.20 92.48

Tiotropium (5 Î¼g) + Olodaterol (5 Î¼g) 1 0.20 92.68

Tiotropium 5 mcg and Placebo 1 0.20 92.89

Tiotropium Bromide Inhalation Capsule.. 1 0.20 93.09

Tofacitinib 10 mg BID 1 0.20 93.29

Tolerability Phase 1 0.20 93.50

Total Therapy 1 0.20 93.70

Treated 1 0.20 93.90

Treatment 1 0.20 94.11

Treatment (Cilengitide) 1 0.20 94.31

Treatment Arm 1 0.20 94.51

Tygacil 1 0.20 94.72

UMEC 62.5 Âµg QD 1 0.20 94.92

UMEC/VI 62.5/25 1 0.20 95.12

US1+US3 1 0.20 95.33

V114 1 0.20 95.53

Valsartan 1 0.20 95.73

Vitamin E + Memantine 1 0.20 95.93

VoluvenÂ® Arm 1 0.20 96.14

Vorapaxar 1 0.20 96.34

Voriconazole 1 0.20 96.54

Voriconazole/Anidulafungin 1 0.20 96.75

Vorinostat 1 0.20 96.95

Vorinostat + Bortezomib 1 0.20 97.15

WATCHMAN 1 0.20 97.36

Warfarin 1 0.20 97.56

Warfarin/Placebo Edoxaban 1 0.20 97.76

Watchful Waiting All: Escalated Yes a.. 1 0.20 97.97

Watchful Waiting Escalated=Yes 1 0.20 98.17

Wire (Control) 1 0.20 98.37

Zilucoplan + SoC 1 0.20 98.58

Zoledronic Acid 4 mg Q4W 1 0.20 98.78

dTpa Group - Infant 1 0.20 98.98

nCPAP Only 1 0.20 99.19

rMenB Lot2 1 0.20 99.39

rhASB 1 0.20 99.59

rhEPO 1 0.20 99.80

tNPWT System 1 0.20 100.00

Here is a list of all the arms that reported 1 or more possible hypoventilation/hypercapnia events.

arm\_title Freq. Percent Cum.

Placebo 139 9.55 9.55

Darbepoetin Alfa 10 0.69 10.23

Total 10 0.69 10.92

Roxadustat 8 0.55 11.47

Vancomycin 7 0.48 11.95

Control Group 5 0.34 12.29

All Patients 4 0.27 12.57

Capecitabine 4 0.27 12.84

Control 4 0.27 13.12

Denosumab 120 mg Q4W 4 0.27 13.39

Epoetin Alfa 4 0.27 13.67

Vadadustat 4 0.27 13.94

Warfarin 4 0.27 14.22

Clopidogrel 3 0.21 14.42

Daprodustat 3 0.21 14.63

Denosumab 3 0.21 14.84

Denosumab 60 mg Q6M 3 0.21 15.04

Glucose Sparing Prescriptions 3 0.21 15.25

Linagliptin 3 0.21 15.45

Linezolid 3 0.21 15.66

Meropenem 3 0.21 15.87

Rivaroxaban (Xarelto, BAY59-7939) 3 0.21 16.07

VI 25 Âµg QD 3 0.21 16.28

XIENCE 3 0.21 16.48

Zoledronic Acid 4 mg Q4W 3 0.21 16.69

10 mg Empagliflozin 2 0.14 16.83

15 mg Tirzepatide 2 0.14 16.96

5 mg Tirzepatide 2 0.14 17.10

Aflibercept 2mg 2 0.14 17.24

Ambrisentan 2 0.14 17.38

Apixaban 2 0.14 17.51

Bivalirudin 2 0.14 17.65

Canagliflozin 100 mg 2 0.14 17.79

Canagliflozin 300 mg 2 0.14 17.93

Chemotherapy 2 0.14 18.06

Chemotherapy Alone 2 0.14 18.20

Cinacalcet 2 0.14 18.34

Control Group - Commercial Surgical A.. 2 0.14 18.48

Dabigatran 110 mg 2 0.14 18.61

Dabigatran 150 mg 2 0.14 18.75

Dapa 10 mg 2 0.14 18.89

Denosumab 180 mg Q4W 2 0.14 19.02

Edoxaban 2 0.14 19.16

Edwards INTUITY Surgical Aortic Heart.. 2 0.14 19.30

Empagliflozin 25 mg 2 0.14 19.44

Endovascular Repair 2 0.14 19.57

Enoxaparin 2 0.14 19.71

Enzalutamide 2 0.14 19.85

Enzalutamide 160 mg 2 0.14 19.99

Epogen 2 0.14 20.12

Ezetimibe 10 mg 2 0.14 20.26

Ferumoxytol 2 0.14 20.40

Finerenone 2 0.14 20.54

Group B 2 0.14 20.67

IV Ceftriaxone 2 0.14 20.81

Ibuprofen 2 0.14 20.95

Ivabradine 2 0.14 21.09

Ixabepilone + Capecitabine 2 0.14 21.22

LA-EP2006 2 0.14 21.36

MK-6072 + SOC 2 0.14 21.50

NIVOLUMAB 2 0.14 21.63

Nintedanib 2 0.14 21.77

Nivolumab 2 0.14 21.91

Nivolumab + Ipilimumab 2 0.14 22.05

PLACEBO 2 0.14 22.18

Palivizumab 2 0.14 22.32

Pegfilgrastim 2 0.14 22.46

Peginesatide 2 0.14 22.60

Peginesatide 0.025 mg/kg 2 0.14 22.73

Peginesatide 0.04 mg/kg 2 0.14 22.87

Pembrolizumab 2 0.14 23.01

Pemetrexed + Carboplatin 2 0.14 23.15

Placebo Group 2 0.14 23.28

Prasugrel 2 0.14 23.42

RO0503821 (1x/2 Weeks) 2 0.14 23.56

Randomized Placebo 2 0.14 23.70

Remdesivir Plus Baricitinib 2 0.14 23.83

Risedronate 2 0.14 23.97

Rivaroxaban 2 0.14 24.11

Roflumilast 2 0.14 24.24

Romosozumab 210 mg 2 0.14 24.38

Simvastatin 2 0.14 24.52

Sorafenib 2 0.14 24.66

Sotagliflozin 2 0.14 24.79

Standard Balloon Angioplasty Catheter 2 0.14 24.93

Standard of Care 2 0.14 25.07

Telavancin 2 0.14 25.21

Ticagrelor 90mg bd 2 0.14 25.34

Tiotropium 2 0.14 25.48

Treatment A 2 0.14 25.62

Treatment Arm 2 0.14 25.76

Usual Care 2 0.14 25.89

Vorapaxar 2 0.14 26.03

Voriconazole 2 0.14 26.17

0.8 mg/kg (500 U/kg) recAP 1 0.07 26.24

1.6 mg/kg (1000 U/kg) recAP 1 0.07 26.30

10 MG/KG IPILIMUMAB 1 0.07 26.37

10 MG/KG Ipilimumab + Paclitaxel/ Car.. 1 0.07 26.44

10 mg Tirzepatide 1 0.07 26.51

100mg QD 1 0.07 26.58

12-Month Double-blind Period: Romosoz.. 1 0.07 26.65

140 mg LY450139- NT 1 0.07 26.72

15 Âµg Iron/dL of Dialysate 1 0.07 26.79

150 mg Abemaciclib + 8 mg/kg Trastuzu.. 1 0.07 26.85

150mg Abemaciclib 1 0.07 26.92

2000 mg Ofatumumab + DR 1 0.07 26.99

3 Ext - Aripiprazole 1 0.07 27.06

3 MG/KG IPILIMUMAB 1 0.07 27.13

36-Month Study Period: Placebo/Denosu.. 1 0.07 27.20

36-Month Study Period: Romosozumab/De.. 1 0.07 27.27

4 Milligrams (mg) Baricitinib 1 0.07 27.34

4200mg Bamlanivimab 1 0.07 27.40

4mg Baricitinib Follow-up 1 0.07 27.47

5-Fluorouracil + Leucovorin 1 0.07 27.54

80 mg Ixe Prefilled Syringe Optional .. 1 0.07 27.61

A - Capecitabine + Enzastaurin 1 0.07 27.68

A and B Comb (C) 1 0.07 27.75

A+AVD 1 0.07 27.82

AAA Repair System 1 0.07 27.88

ABBV-8E12 4000mg 1 0.07 27.95

ABI-007 Arm A 1 0.07 28.02

ACT-064992 10 mg 1 0.07 28.09

ACT-064992 3 mg 1 0.07 28.16

ADS-5102 (Amantadine HCl Extended Rel.. 1 0.07 28.23

AMX0035 1 0.07 28.30

AR-105 1 0.07 28.37

ARDFP + Mega ART 1 0.07 28.43

ARM B (ZDV + NVP) 1 0.07 28.50

ART-123 1 0.07 28.57

ASA 100mg 1 0.07 28.64

ASP0113 5mg 1 0.07 28.71

Abiraterone Acetate 1 0.07 28.78

Abrocitinib 200 mg QD 1 0.07 28.85

Absorb BVS 1 0.07 28.91

Acalabrutinib - Arm A 1 0.07 28.98

Acetylsalicylic Acid, Aspirin (ASA) 1.. 1 0.07 29.05

Aclidinium Bromide 1 0.07 29.12

Aclidinium Bromide 400 Î¼g - Part A 1 0.07 29.19

Active Best Supportive Care (BSC) 1 0.07 29.26

Active Inhaled Treprostinil 1 0.07 29.33

Adalimumab EW/Adalimumab EOW (Period 2) 1 0.07 29.40

Adjusted MMF + Tacrolimus + CS 1 0.07 29.46

AdreViewâ¢ 1 0.07 29.53

Afatinib (BIBW 2992) 1 0.07 29.60

Afatinib 40 mg 1 0.07 29.67

Afatinib 50 mg / Cetuximab 250mg/m2 -.. 1 0.07 29.74

Afatinib 50 mg/Day 1 0.07 29.81

Afatinib Monotherapy (Part A) 1 0.07 29.88

Afatinib Plus Paclitaxel (Part B) 1 0.07 29.95

Aflibercept 2.0 mg/kg 1 0.07 30.01

After the Infant Series 7vPnC 1 0.07 30.08

After the Infant Series Combined 13vPnC 1 0.07 30.15

Aggrenox Capsule 1 0.07 30.22

Alair 1 0.07 30.29

Albiglutide 1 0.07 30.36

Albiglutide 30 mg Plus Metformin 1 0.07 30.43

Albumin 1 0.07 30.49

Alemtuzumab High-Risk Patients 1 0.07 30.56

Alendronate 1 0.07 30.63

Alirocumab 1 0.07 30.70

Alirocumab 150 mg Q4W (After Alirocum.. 1 0.07 30.77

Aliskiren 1 0.07 30.84

All Implanted Cohort 1 0.07 30.91

All Participants 1 0.07 30.98

All Patients With IPF - Overall Popul.. 1 0.07 31.04

All Placebo 1 0.07 31.11

All Tocilizumab 8 mg/kg + Methotrexate 1 0.07 31.18

AlloDerm, Integra, Homograft, Autograft 1 0.07 31.25

Allopurinol 1 0.07 31.32

Alogliptin 1 0.07 31.39

Alternative Therapy 1 0.07 31.46

Ambrisentan 10 mg 1 0.07 31.52

Ambrisentan 2.5 mg 1 0.07 31.59

Ambrisentan 5 mg 1 0.07 31.66

Amlodipine Failed Group 1 0.07 31.73

Amphotericin B Deoxycholate 1 0.07 31.80

Anastrozole 1 0.07 31.87

Anastrozole 1 mg 1 0.07 31.94

Andecaliximab + mFOLFOX6 1 0.07 32.01

Antiplatelet Arm 1 0.07 32.07

Any Secukinumab 75 mg 1 0.07 32.14

Apalutamide 1 0.07 32.21

Apaziquone 1 0.07 32.28

Apix 2.5mg BID 1 0.07 32.35

Apixaban 5 mg BID 1 0.07 32.42

Apixaban 5mg 1 0.07 32.49

Apixaban With Placebo Matching Acetyl.. 1 0.07 32.55

Apixaban, 2.5 or 5 mg Twice Daily 1 0.07 32.62

Apremilast + SoC 1 0.07 32.69

Apremilast 30 mg BID (APR Exposure Pe.. 1 0.07 32.76

Apremilast Placebo + SoC 1 0.07 32.83

Aprepitant 1 0.07 32.90

Aprepitant 40 mg Adult Equivalent (Do.. 1 0.07 32.97

Aripiprazole 10 mg/Day 1 0.07 33.04

Aripiprazole IM Depot- Double-blind, .. 1 0.07 33.10

Arm 1: 5-fluorouracil 1 0.07 33.17

Arm 1: Inactive Substance 1 0.07 33.24

Arm 2: Methylprednisolone 1 0.07 33.31

Arm 2: Placebo 1 0.07 33.38

Arm A (Atezolizumab+Nab-Paclitaxel+Ca.. 1 0.07 33.45

Arm A. Verubecestat 12 mg [Part II] 1 0.07 33.52

Arm A: 1 0.07 33.59

Arm A: Nivolumab + Chemotherapy (XELO.. 1 0.07 33.65

Arm A: Rituximab Retreatment 1 0.07 33.72

Arm B. Verubecestat 40 mg (Part 2) 1 0.07 33.79

Arm B. Verubecestat 40 mg [Part I] 1 0.07 33.86

Arm B: Atezolizumab + Nab-Paclitaxel .. 1 0.07 33.93

Arm B: Chemotherapy (XELOX or FOLFOX) 1 0.07 34.00

Arm B: Fulvestrant 500 mg + Sapaniser.. 1 0.07 34.07

Arm B: Pomalidomide+Dexamethasone 1 0.07 34.13

Arm C: Nivolumab + Ipilimumab 1 0.07 34.20

Arm E: Ranibizumab 0.5 mg + Faricimab.. 1 0.07 34.27

Aspirin + Extended Release Dipyridamo.. 1 0.07 34.34

Aspirin + Extended Release Dipyridamo.. 1 0.07 34.41

Atorvastatin 20 mg 1 0.07 34.48

Avelumab + BSC 1 0.07 34.55

Avelumab + Standard of Care Chemother.. 1 0.07 34.62

Axitinib 1 0.07 34.68

Axitinib (First-line Participants) 1 0.07 34.75

Azacitidine 1 0.07 34.82

Azacitidine 75 mg/m^2 1 0.07 34.89

Azacitidine 75 mg/m^2 + Pevonedistat .. 1 0.07 34.96

B - Capecitabine + Placebo 1 0.07 35.03

B.2 Lucinactant 1 0.07 35.10

BA058 80 mcg (Abaloparatide) 1 0.07 35.16

BFF MDI 320/9.6 Î¼g 1 0.07 35.23

BGF MDI 160/14.4/9.6 Î¼g 1 0.07 35.30

BGF MDI 320/14.4/9.6 Î¼g 1 0.07 35.37

BIIB092 2000 mg (Placebo Controlled P.. 1 0.07 35.44

BIIB092 Late Start (Open-label Extens.. 1 0.07 35.51

BIOTRONIK Siello S Lead 1 0.07 35.58

BLM 240 N2O Group 1 0.07 35.65

BSC-R 1 0.07 35.71

BUD/FOR 400/12 Âµg 1 0.07 35.78

BYM338 700 mg 1 0.07 35.85

Basal Bolus Prior Lispro LM Addendum 1 0.07 35.92

Base Study + First Extension: Odanaca.. 1 0.07 35.99

Base Study + First Extension: Placebo 1 0.07 36.06

Belatacept - LI 1 0.07 36.13

Belatacept - MI 1 0.07 36.20

Belatacept More Intensive (MI) Regimen 1 0.07 36.26

Belimumab 10 mg/kg 1 0.07 36.33

Belumosudil-WC 1 0.07 36.40

Bempegaldesleukin + Nivolumab 1 0.07 36.47

Benra 10 mg 1 0.07 36.54

Benra 100 mg 1 0.07 36.61

Benra 30 mg 1 0.07 36.68

Benralizumab 100 mg 1 0.07 36.74

BeriplexÂ® P/N 1 0.07 36.81

Best Supportive/Best Standard of Care.. 1 0.07 36.88

Betrixaban 1 0.07 36.95

Bevacizumab 1 0.07 37.02

Bevacizumab + mFOLFOX6 1 0.07 37.09

Bevacizumab Plus Capecitabine 1 0.07 37.16

Bevacizumab Plus mFOLFOX6 1 0.07 37.23

Bevacizumab With Chemotherapy 1 0.07 37.29

Bevacizumab and Chemotherapy (0-18 Mo.. 1 0.07 37.36

Bevacizumab+ Interferon-Alfa 1 0.07 37.43

Bevacizumab+Oxaliplatin+Capecitabine/.. 1 0.07 37.50

Bevacizumab-EU 1 0.07 37.57

Bexagliflozin Tablets, 20 mg 1 0.07 37.64

Bicalutamide 50 mg/Placebo 1 0.07 37.71

Binimetinib (MEK162) 1 0.07 37.77

Bisphosphonate IV Q4W 1 0.07 37.84

Biventricular Pacing Arm 1 0.07 37.91

Blinatumomab 1 0.07 37.98

Bococizumab (PF-04950615) 1 0.07 38.05

Bortezomib + Dexamethasone 1 0.07 38.12

Bortezomib and Dexamethasone 1 0.07 38.19

Bosentan 1 0.07 38.26

Bosutinib 1 0.07 38.32

Brisdelle (Paroxetine Mesylate) Capsu.. 1 0.07 38.39

Buparlisib (BKM120) 100 mg Plus Pacli.. 1 0.07 38.46

C21 Treatment 1 0.07 38.53

C: Aflibercept 2 mg Q8W 1 0.07 38.60

CAB LA + RPV LA Q8W 1 0.07 38.67

CB-839 + Everolimus 1 0.07 38.74

CC-486+Pembrolizumab 1 0.07 38.80

CD24Fc 1 0.07 38.87

CF-301 1 0.07 38.94

CF102 1 0.07 39.01

CRT: Not Randomized 1 0.07 39.08

CS7017-matching Placebo+Carboplatin+P.. 1 0.07 39.15

CTAG Device Aneurysm Subjects 1 0.07 39.22

Cadazolid 1 0.07 39.29

Canagliflozin (Experimental) 1 0.07 39.35

CapeOx + Lapatinib 1 0.07 39.42

Capecitabine Plus Cisplatin 1 0.07 39.49

Carfilzomib 1 0.07 39.56

Caspofungin (CAS)/Voriconazole 1 0.07 39.63

Caspofungin 150 mg 1 0.07 39.70

Caspofungin 70/50 mg 1 0.07 39.77

Cefiderocol 1 0.07 39.84

Ceftolozane/Tazobactam 1 0.07 39.90

Celecoxib 1 0.07 39.97

Cetuximab & Pemetrexed 1 0.07 40.04

Cetuximab Plus Capecitabine Plus Cisp.. 1 0.07 40.11

Cetuximab Plus Chemotherapy 1 0.07 40.18

Cetuximab Plus FOLFOX 1 0.07 40.25

Cetuximab Plus FOLFOX-4 1 0.07 40.32

Cetuximab and Docetaxel 1 0.07 40.38

Cetuximab+Taxane+Carboplatin 1 0.07 40.45

Chemotherapy (SOC Treatment) 1 0.07 40.52

Chemotherapy (Vinflunine, Paclitaxel,.. 1 0.07 40.59

Chemotherapy Plus Radiotherapy 1 0.07 40.66

Chronic Kidney Disease, Secondary Hyp.. 1 0.07 40.73

Cladribine 3.5 mg/kg, Rebif (OLMP) 1 0.07 40.80

Cladribine 5.25 mg/kg 1 0.07 40.87

Clofarabine (IV Formulation) and Cyta.. 1 0.07 40.93

Clopidogrel / Placebo 1 0.07 41.00

Clopidogrel / Telmisartan 1 0.07 41.07

Clopidogrel 0.2mg/kg/Day 1 0.07 41.14

Clopidogrel 300/75/75 mg + ASA High D.. 1 0.07 41.21

Clopidogrel 300/75/75 mg + ASA Low Dose 1 0.07 41.28

Clopidogrel 600/150/75 mg + ASA High .. 1 0.07 41.35

Clopidogrel 75mg od 1 0.07 41.41

Co-Ad Group 1 0.07 41.48

Cohort 1 (Treatment-experienced) 1 0.07 41.55

Cohort 1, Single-agent Dose-finding: .. 1 0.07 41.62

Cohort 1b: Arm N3+I1 1 0.07 41.69

Cohort A-5 (Roxadustat 1.8 mg/kg TIW) 1 0.07 41.76

Cohort B 1 0.07 41.83

Cohort B PradaxaÂ® 1 0.07 41.90

Cohort C 1 0.07 41.96

Cohort2B,Single-agentExpansion,Osteos.. 1 0.07 42.03

Combination 1 0.07 42.10

Combination GP2013+CVP 1 0.07 42.17

Combination Therapy 1 0.07 42.24

Combination Therapy (Cohort B): Place.. 1 0.07 42.31

Combination Therapy: Ambrisentan + Ta.. 1 0.07 42.38

Combination of Aliskiren and Enalapril 1 0.07 42.45

Comparitor Protease Inhibitor(CPI)/Lo.. 1 0.07 42.51

Control (Standard-of-Care) 1 0.07 42.58

Control - Manual Compression With Sur.. 1 0.07 42.65

Control Arm 1 0.07 42.72

Conventional 3D-CRT 1 0.07 42.79

Convergent Procedure 1 0.07 42.86

Cook CelectÂ® Vena Cava Filters 1 0.07 42.93

CoreValve TAVR System - Randomized 1 0.07 42.99

Corifollitropin Alfa 150 Î¼g Follow-u.. 1 0.07 43.06

Coronary Artery Bypass Graft (CABG) 1 0.07 43.13

Creatine 1 0.07 43.20

Crossover Phase: Brigatinib 90 mg QD/.. 1 0.07 43.27

CsA+MMF+CS 1 0.07 43.34

Cyclophosphamide/Doxorubicin/Vincrist.. 1 0.07 43.41

Cyclosporin (CsA) 1 0.07 43.48

Cyclosporine 1 0.07 43.54

Cyklokapron 1 0.07 43.61

Cysteamine Bitartrate Delayed-release 1 0.07 43.68

DAC HYP 150 mg 1 0.07 43.75

DB: Denosumab 120 mg Q4W 1 0.07 43.82

DB: Zoledronic Acid 1 0.07 43.89

DI (Degarelix Intermittent) 1 0.07 43.96

DOCETAXEL 1 0.07 44.02

DOXIL + Thalidomide + Dexamethasone 1 0.07 44.09

DOXIL+Docetaxel 1 0.07 44.16

DRV/Rtv 800/100 mg Once Daily 1 0.07 44.23

DU-176b 15 mg 1 0.07 44.30

Dabigatran 1 0.07 44.37

Dabigatran Etexilate (1) 1 0.07 44.44

Dabigatran Etexilate (2) 1 0.07 44.51

Dabigatran Etexilate (PradaxaÂ®) 1 0.07 44.57

Dabigatran Etexilate - Baseline (Phas.. 1 0.07 44.64

Dabigatran Etexilate 110mg 1 0.07 44.71

Dacarbazine 1 0.07 44.78

Daily Nutriceutical Supplementation 1 0.07 44.85

Dalcetrapib 1 0.07 44.92

Dalteparin Group 1 0.07 44.99

Dapa 10mg 1 0.07 45.05

Dapagliflozin 2.5mg + Glimepiride 1 0.07 45.12

Dapagliflozin, 2.5 mg + Metformin 1 0.07 45.19

Darapladib 1 0.07 45.26

Darapladib 160 mg 1 0.07 45.33

Daratumumab + Lenalidomide + Dexameth.. 1 0.07 45.40

Dasatinib 1 0.07 45.47

Dasatinib 140 mg QD 1 0.07 45.54

Dasatinib 70 mg BID 1 0.07 45.60

Degarelix 240@40/240@60 (1,3,6,9) 1 0.07 45.67

Delayed Start Treatment 1 0.07 45.74

Delayed Start: Placebo 1 0.07 45.81

Denosumab 120 mg 1 0.07 45.88

Denosumab 60 mg SC Q6M 1 0.07 45.95

Device Closure 1 0.07 46.02

Device: ICAST Covered Stent 1 0.07 46.09

Dexpramipexole 1 0.07 46.15

Docetaxel 1 0.07 46.22

Docetaxel 75 mg/m^2 1 0.07 46.29

Docetaxel/Prednisone/Lenalidomide (DPL) 1 0.07 46.36

Donepezil + SB-742457 15 mg 1 0.07 46.43

Donepezil Period 1 1 0.07 46.50

Doripenem 1 0.07 46.57

Double Oral Therapy (Macitentan, Tada.. 1 0.07 46.63

Double-Blind Atrasentan 1 0.07 46.70

Double-Blind Placebo 1 0.07 46.77

Double-Blind Treatment Phase B/F/TAF 1 0.07 46.84

Double-blind Period: Romosozumab 210 .. 1 0.07 46.91

Drotrecogin Alfa (Activated) 1 0.07 46.98

Dulaglutide 1 0.07 47.05

Dulaglutide 0.75 mg 1 0.07 47.12

Dulaglutide 1.5 mg 1 0.07 47.18

Dulaglutide 3 mg 1 0.07 47.25

Dulaglutide 4.5 mg 1 0.07 47.32

Dupilumab 300 mg q2w 1 0.07 47.39

Durvalumab 1 0.07 47.46

Durvalumab + Tremelimumab 1 0.07 47.53

Dutasteride 0.5 mg 1 0.07 47.60

E-Ld Cohort 1 0.07 47.66

ELAD System 1 0.07 47.73

ELAD Treatment 1 0.07 47.80

EP: IncobotulinumtoxinA (Xeomin) (75 .. 1 0.07 47.87

ESA (Erythropoiesis-Stimulating Agent) 1 0.07 47.94

ETN/IXE80Q4W Long-Term Extension 1 0.07 48.01

EXXCEL Soft 1 0.07 48.08

Early Start Treatment 1 0.07 48.15

Early Start: GA 40 mg / GA 40 mg 1 0.07 48.21

Empa 25mg 1 0.07 48.28

Empagliflozin 10 mg 1 0.07 48.35

Enalapril 1 0.07 48.42

Endovascular 1 0.07 48.49

Endovascular Thrombectomy Therapy 1 0.07 48.56

Enox 40mg QD 1 0.07 48.63

Enoxaparin 30 mg SC Injection q 12 Ho.. 1 0.07 48.70

Enoxaparin/VKA 1 0.07 48.76

Enrichment Atrasentan 1 0.07 48.83

Entire Any AIN457 150 mg 1 0.07 48.90

Enzalutamide + Androgen Deprivation T.. 1 0.07 48.97

Enzastaurin/Pemetrexed/Carboplatin 1 0.07 49.04

Epanova 1 0.07 49.11

Eplerenone 1 0.07 49.18

Eplerenone: Open Label Phase 1 0.07 49.24

Epoetin 1 0.07 49.31

Epoetin (1-3x/Weeks) 1 0.07 49.38

Epoetin Alfa Alternative Titration 1 0.07 49.45

Epoetin Alfa Q2W 1 0.07 49.52

Epoetin Alfa Q4W 1 0.07 49.59

Epoetin Alfa:Once Weekly (QW) 1 0.07 49.66

Epoetin Hospira 1 0.07 49.73

Epoetin Reference 1 0.07 49.79

Epogen: Maintenance Period 1 0.07 49.86

Eribulin Mesylate, 28 Day Cycle 1 0.07 49.93

Erlotinib 1 0.07 50.00

Erlotinib (Early Erlotinib) 1 0.07 50.07

Erlotinib, 150 mg/Day 1 0.07 50.14

Ertapenem 1 0.07 50.21

Ertugliflozin 15 mg (Overall Cardiova.. 1 0.07 50.27

Ertugliflozin 5 mg (Overall Cardiovas.. 1 0.07 50.34

Erythropoiesis Stimulating Agents 1 0.07 50.41

Esomeprazole 1 0.07 50.48

Etanercept 1 0.07 50.55

Etanercept + Clobetasol Propionate Foam 1 0.07 50.62

Etelcalcetide 1 0.07 50.69

Etoposide + Carboplatin 1 0.07 50.76

Evacetrapib 1 0.07 50.82

Everolimus (RAD001) 1 0.07 50.89

Everolimus 10 mg 1 0.07 50.96

Everolimus 10 mg + Exemestane 25 mg 1 0.07 51.03

Everolimus 1L/Sunitinib 2L 1 0.07 51.10

Everolimus Plus@Reduced CNI 1 0.07 51.17

Everolimus+ Paclitaxel+ Trastuzumab 1 0.07 51.24

Evolocumab 1 0.07 51.30

Expansion Cohort 2 1 0.07 51.37

Expansion UC Cohort (MEDI4736 10 mg/k.. 1 0.07 51.44

Experimental: Arformoterol 15 Mcg Twi.. 1 0.07 51.51

Extension Phase (Phase C) 1 0.07 51.58

Extension: Placebo-FTY0.5 1 0.07 51.65

Ezetimide/Simvastatin 1 0.07 51.72

F/TAF (Double-Blind Phase) 1 0.07 51.79

FF/UMEC/VI 100/62.5/25 1 0.07 51.85

FF/VI 1 0.07 51.92

FF/VI 100 mcg/25 mcg 1 0.07 51.99

FF/VI 100/25 1 0.07 52.06

FF/VI 100/25 + UMEC 62.5 1 0.07 52.13

FF/VI 100/25 Âµg + Placebo 1 0.07 52.20

FF/VI 100/25 Âµg QD 1 0.07 52.27

FIRMAGON 1 0.07 52.34

FKB238 / Paclitaxel / Carboplatin 1 0.07 52.40

FOLFIRI + Placebo 1 0.07 52.47

FOLFOX Alone 1 0.07 52.54

FORTEO (Teriparatide)-Treated 1 0.07 52.61

FOSTA 100 MG BID (4 WKS) THEN 150 MG .. 1 0.07 52.68

FP-1201-lyo 10 Î¼g 1 0.07 52.75

FSC 250/50 Âµg BID 1 0.07 52.82

Fasiglifam 50 mg 1 0.07 52.88

Favipiravir + Supportive Care 1 0.07 52.95

Febuxostat IR 80 mg 1 0.07 53.02

Figitumumab + Paclitaxel and Carbopla.. 1 0.07 53.09

FlowTriever System 1 0.07 53.16

Fluoropyrimidine/Cisplatin (FP) 1 0.07 53.23

Fluticasone Furoate 100 Âµg 1 0.07 53.30

Fluticasone Furoate/Umeclidinium/Vila.. 1 0.07 53.37

Fluticasone Furoate/Vilanterol 100/25.. 1 0.07 53.43

Fluticasone Maintenance 1 0.07 53.50

Fluticasone Withdrawal 1 0.07 53.57

Focal/Grid Laser Photocoagulation 1 0.07 53.64

Formoterol 12 Î¼g 1 0.07 53.71

Fosaprepitant 1 0.07 53.78

Frail-HZ/su 1 0.07 53.85

Frail-Placebo 1 0.07 53.91

GFF MDI 14.4/9.6 Î¼g 1 0.07 53.98

GORE Conformable TAGÂ® Device Surgica.. 1 0.07 54.05

GSK1278863 300 mg Loading + 100 mg QD 1 0.07 54.12

GSK1437173A Lot C Group 1 0.07 54.19

GSK1572932 Group 1 0.07 54.26

GSK249320 15 mg/kg 1 0.07 54.33

GSK257049 [6-12W] Group 1 0.07 54.40

Gel-200 1 0.07 54.46

Gem + Carb or Cis (Squamous) 1 0.07 54.53

Gemcitabine + Cisplatin 1 0.07 54.60

Gemcitabine/Carboplatin Induction 1 0.07 54.67

Gemcitabine/Cisplatin/Radiation 1 0.07 54.74

Gilteritinib 1 0.07 54.81

Gimsilumab 1 0.07 54.88

Glimepiride 1 0.07 54.95

Glipizide 2.5 mg - 20 mg 1 0.07 55.01

Global: Durvalumab + Tremelimumab 1 0.07 55.08

Group 1 - Dosing Without Food 1 0.07 55.15

Group 1 - FCM (Ferric Carboxymaltose) 1 0.07 55.22

Group 1: REGN2176-3 (1 mg:2 mg) 1 0.07 55.29

Group 2 - BSC Alone 1 0.07 55.36

Group 2 - Placebo (Normal Saline (NaC.. 1 0.07 55.43

Group B: Golimumab 100 mg SC Injectio.. 1 0.07 55.49

Group C: CNI Reduction 1 0.07 55.56

Group I 1 0.07 55.63

Group II 1 0.07 55.70

Group III 1 0.07 55.77

Group IV 1 0.07 55.84

Group V 1 0.07 55.91

GÃ¼nther TulipÂ® Vena Cava Filter 1 0.07 55.98

HBeAg Positive 1 0.07 56.04

HCRI DAPT - BMS 12-month DAPT 1 0.07 56.11

HCRI DAPT - BMS 30-month DAPT 1 0.07 56.18

HCRI DAPT - DES 12-month DAPT 1 0.07 56.25

HEPLISAV-B 1 0.07 56.32

HX575 Epoetin Alfa 1 0.07 56.39

Havrix Group 1 0.07 56.46

Hb-Based Titration Group 1 0.07 56.52

Heparin Arm 1 0.07 56.59

Heparin/Edoxaban Tosylate 1 0.07 56.66

High Dose Edoxaban/Placebo Warfarin 1 0.07 56.73

High GR270773 1 0.07 56.80

High Quality Anticoagulation Manageme.. 1 0.07 56.87

High-dose Everolimus Group 1 0.07 56.94

Hydrocodone ER (Open-Label Titration .. 1 0.07 57.01

IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 1 0.07 57.07

ICS Plus LABA Plus LAMA (Triple Thera.. 1 0.07 57.14

IGlar U300 1 0.07 57.21

IMC-1121B (Ramucirumab) 1 0.07 57.28

IMI/REL 1 0.07 57.35

IN.PACT AV DCB 1 0.07 57.42

IRBESARTAN 1 0.07 57.49

IV Docetaxel 1 0.07 57.55

IV Insulin Drip With Target Glucose 8.. 1 0.07 57.62

IV Isotonic Saline & Oral N-acetylcys.. 1 0.07 57.69

IV Isotonic Saline & Oral Placebo 1 0.07 57.76

IV Only 1 0.07 57.83

IV Topotecan + IV Docetaxel 1 0.07 57.90

Ibrutinib + BR (Treatment B) 1 0.07 57.97

Ibrutinib+BR 1 0.07 58.04

Idelalisib+Ofatumumab 1 0.07 58.10

Iloprost 1 0.07 58.17

Iloprost PD-15 1 0.07 58.24

Imatinib 1 0.07 58.31

Imipenem-cilastatin 1 0.07 58.38

Inclisiran 1 0.07 58.45

Individualized Medical Therapy (IMT) 1 0.07 58.52

Induction AIN457 150 mg 1 0.07 58.59

Induction Pemetrexed + Cisplatin 1 0.07 58.65

Infant (Vitamin C) 1 0.07 58.72

Infant Chloroquine Prophylaxis 1 0.07 58.79

Infant SP IPT 1 0.07 58.86

Inhaled Nitric Oxide 1 0.07 58.93

Inhaled Nitric Oxide (INO) 1 0.07 59.00

Insulin Degludec 1 0.07 59.07

Insulin Degludec/Liraglutide 1 0.07 59.13

Insulin Glargine 1 0.07 59.20

Insulin Glargine Maintenance 1 0.07 59.27

Intensive Renal Replacement Therapy 1 0.07 59.34

Intravenous (IV) Zanamivir 300mg Twic.. 1 0.07 59.41

Investigator's Choice 1 0.07 59.48

Investigator's Choice Chemotherapy 1 0.07 59.55

Ipilimumab 1 0.07 59.62

Ipilimumab + Radiotherapy 1 0.07 59.68

Ipilimumab Plus gp100 1 0.07 59.75

Irbesartan 1 0.07 59.82

Iron Sucrose 1 0.07 59.89

Isavuconazole 1 0.07 59.96

Isavuconazole (ISA) 1 0.07 60.03

Ixabepilone 16 mg/m^2 1 0.07 60.10

Ixabepilone, 40 mg/m^2, Intravenously.. 1 0.07 60.16

Ixazomib+ Lenalidomide + Dexamethasone 1 0.07 60.23

KRX-0502 (SAP) 1 0.07 60.30

KdD - Carfilzomib, Dexamethasone and .. 1 0.07 60.37

Kyphoplasty 1 0.07 60.44

LCZ696 1 0.07 60.51

LCZ696 (Sacubitril/Valsartan) 1 0.07 60.58

LI + CIZ + SOC 1 0.07 60.65

LJPC-501 (Angiotensin II) 1 0.07 60.71

LY2127399 1 0.07 60.78

LY2510924 + Sunitinib 1 0.07 60.85

Lampalizumab Q6W 1 0.07 60.92

Lanabecestat 20 Mg-Period 1 1 0.07 60.99

Lanabecestat 20 mg 1 0.07 61.06

Lanadelumab + SoC 1 0.07 61.13

Lantus 1 0.07 61.20

Lapatinib 1 0.07 61.26

Lapatinib 1000/750 mg + Trastuzumab 2.. 1 0.07 61.33

Lapatinib plusTrastuzumab 1 0.07 61.40

Laser Photocoagulation 1 0.07 61.47

Ld Cohort 1 0.07 61.54

Lead-in Period Sibutramine 1 0.07 61.61

Left Atrial Ablation 1 0.07 61.68

Lenalidomide 1 0.07 61.74

Lenalidomide + Dexamethasone + Elotuz.. 1 0.07 61.81

Lenalidomide and Dexamethasone (Rd18) 1 0.07 61.88

Lenvatinib + Pembrolizumab 1 0.07 61.95

Lenvatinib 20 mg Plus Pembrolizumab 2.. 1 0.07 62.02

Less-intensive Renal Replacement Ther.. 1 0.07 62.09

Letrozole 1 0.07 62.16

Leuprolide Acetate 1 0.07 62.23

Levodopa-Carbidopa Intestinal Gel 1 0.07 62.29

Licensed TIV 1 0.07 62.36

Linagliptin 5.0 mg 1 0.07 62.43

Liposomal Amphotericin B 1 0.07 62.50

Liraglutide 1 0.07 62.57

Liraglutide 3.0 mg, Pre-diabetes 1 0.07 62.64

Liraglutide Placebo, Pre-diabetes 1 0.07 62.71

Lispro LM Initiation 1 0.07 62.77

Lixisenatide 1 0.07 62.84

Long Acting B2 Agonist (LABA) and Inh.. 1 0.07 62.91

Lorcaserin 10 mg 1 0.07 62.98

Losartan 50 mg 1 0.07 63.05

Losartan-Based Regimen Alone (L Group) 1 0.07 63.12

Losmapimod 15 mg Followed by Losmapim.. 1 0.07 63.19

Losmapimod 7.5 mg (A) 1 0.07 63.26

Lotus Valve System - Randomized 1 0.07 63.32

Lotus Valve System - Single-arm Conti.. 1 0.07 63.39

Low Dose Edoxaban/Placebo Warfarin 1 0.07 63.46

Low GR270773 1 0.07 63.53

Low-dose Cytarabine Plus Arsenic Trio.. 1 0.07 63.60

Lurbinectedin 1 0.07 63.67

Lurbinectedin/Doxorubicin 1 0.07 63.74

Lutonix DCB 1 0.07 63.80

MAS825 + SoC 1 0.07 63.87

MB02 (Bevacizumab Biosimilar Drug) 1 0.07 63.94

MEDI3902 1500 mg 1 0.07 64.01

MEDI4893 2000 mg 1 0.07 64.08

MEDI4893 5000 mg 1 0.07 64.15

MHAA4549A 3600 mg + Oseltamivir 1 0.07 64.22

MIRCERA 1 0.07 64.29

MISTIE Surgical Management 1 0.07 64.35

MK-3415A + SOC 1 0.07 64.42

MK-6072 + SOC 9-ME 1 0.07 64.49

MK-6096 10 mg - Run-in Period 1 0.07 64.56

MO.MA Pivotal Subjects 1 0.07 64.63

MORAb-003 (Farletuzumab) Plus Paclita.. 1 0.07 64.70

MP Mid Dose Group 1 0.07 64.77

MSTT1041A 1 0.07 64.84

MYL-1402O 1 0.07 64.90

MYOBLOC 3500 U (Part A) 1 0.07 64.97

Macitentan 1 0.07 65.04

Magnesium Sulfate 1 0.07 65.11

Maraviroc BID 1 0.07 65.18

Maraviroc Exposed 1 0.07 65.25

Maraviroc Unexposed 1 0.07 65.32

Maribavir 100 mg BID 1 0.07 65.38

Matched Placebo (Plus Usual Hospital .. 1 0.07 65.45

Matching Placebo 1 0.07 65.52

Medical Management 1 0.07 65.59

Memantine 1 0.07 65.66

Mepolizumab 1 0.07 65.73

Mepolizumab 100 mg SC 1 0.07 65.80

Mepolizumab 300 mg SC 1 0.07 65.87

Metformin 1 0.07 65.93

Methoxy Polyethylene Glycol-Epoetin B.. 1 0.07 66.00

Metoprolol Succinate 1 0.07 66.07

Micra Pacemaker Implant 1 0.07 66.14

MitraClip System 1 0.07 66.21

Mitral Valve Repair With Annuloplasty 1 0.07 66.28

Monotherapy 1 0.07 66.35

Monotherapy ARB 1 0.07 66.41

Month 48-72: Romosozumab/Denosumab/Ro.. 1 0.07 66.48

Motavizumab (MEDI-524) 1 0.07 66.55

Moxifloxacin (Avelox, BAY12-8039) 1 0.07 66.62

Mycobutin (Rifabutin) 1 0.07 66.69

Nab-Paclitaxel + Best Supportive Care.. 1 0.07 66.76

Naproxen 1 0.07 66.83

Navarixin 10 mg 1 0.07 66.90

Necitumumab + Gemcitabine + Cisplatin 1 0.07 66.96

Necitumumab+Pemetrexed+Cisplatin 1 0.07 67.03

Neladenoson Bialanate 10mg 1 0.07 67.10

Nemolizumab (10 mg) 1 0.07 67.17

Neoadjuvant Phase: ABP 980 1 0.07 67.24

Neonate (Azithromycin + Chloroquine) 1 0.07 67.31

Neratinib+Paclitaxel 1 0.07 67.38

Neutrolin Arm 1 0.07 67.45

Nilotinib 300 mg BID 1 0.07 67.51

Nintedanib 50 Bid 1 0.07 67.58

Nintedanib Plus Docetaxel 1 0.07 67.65

Nintedanib Plus Pemetrexed 1 0.07 67.72

Nintedanib\_Phase III 1 0.07 67.79

Nivolumab 3mg/kg 1 0.07 67.86

No ARDFP + Mega ART 1 0.07 67.93

Non-Frail-HZ/su 1 0.07 67.99

Normal Renal Function 1 0.07 68.06

Normal Saline 1 0.07 68.13

Not Assigned to Dabigatran Etexilate .. 1 0.07 68.20

Nusinersen 1 0.07 68.27

OBSERVATION 1 0.07 68.34

OL: ALL MYOBLOC (Part B) 1 0.07 68.41

OL: Zoledronic Acid / Denosumab 1 0.07 68.48

OLM 40-AML 10-HCTZ 25 1 0.07 68.54

ONO-4538 Group 1 0.07 68.61

ORION 1 0.07 68.68

Obinutuzumab+Chemotherapy 1 0.07 68.75

Observation 1 0.07 68.82

Observational Cohort 1 0.07 68.89

Ofa + Benda (Arm A) 1 0.07 68.96

Ofa + Benda (Arm A) + Benda (Arm B) +.. 1 0.07 69.02

Ofatumumab 1000 mg + Chlorambucil 1 0.07 69.09

Olesoxime 1 0.07 69.16

Olmesartan 1 0.07 69.23

Olo 5 mcg 1 0.07 69.30

Olodaterol (Olo) 5 mcg qd 1 0.07 69.37

Omadacycline 1 0.07 69.44

Omecamtiv Mecarbil 1 0.07 69.51

Omecamtiv Mecarbil 25 mg BID 1 0.07 69.57

Onasemnogene Abeparvovec-xioi 1 0.07 69.64

Open Label Apixaban 1 0.07 69.71

Open Repair 1 0.07 69.78

Open-Label Treatment (Pirfenidone) 1 0.07 69.85

Open-label CR845 0.5 mcg/kg 1 0.07 69.92

Open-label CR845 0.5mcg/kg 1 0.07 69.99

Oral Semaglutide 1 0.07 70.05

Oral Semaglutide 7 mg 1 0.07 70.12

Orsiro Sirolimus Coronary Stent System 1 0.07 70.19

Orteronel + Prednisone 1 0.07 70.26

Orteronel 400 mg + Prednisone 5 mg 1 0.07 70.33

Overall 1 0.07 70.40

Overall Study 1 0.07 70.47

Overall Study: Alendronate / Alendron.. 1 0.07 70.54

Overall Study: Romosozumab / Alendron.. 1 0.07 70.60

PAG: PEGPH20 + Nab-paclitaxel + Gemci.. 1 0.07 70.67

PAR-101/OPT-80 1 0.07 70.74

PEG + RBV 1 0.07 70.81

PEGASYS 180 ug/wk Plus COPEGUS 1 0.07 70.88

PF-05280014 1 0.07 70.95

PF-06647020 2.8 mg/kg (Q3W Regimen) 1 0.07 71.02

PIP/TAZ 1 0.07 71.09

PROMUS 1 0.07 71.15

PROMUS Element 1 0.07 71.22

Pac/Carbo/Bev 1 0.07 71.29

Paclitaxel 1 0.07 71.36

Paclitaxel + Carboplatin 1 0.07 71.43

Paclitaxel and Carboplatin (Chemo) 1 0.07 71.50

Palbociclib + Cetuximab 1 0.07 71.57

Palonosetron 20 mcg/kg 1 0.07 71.63

Panit. Plus Bevacizumab With Chemothe.. 1 0.07 71.70

Panitumumab Plus BSC 1 0.07 71.77

Panitumumab Plus Chemoradiation 1 0.07 71.84

Panitumumab Plus Chemotherapy 1 0.07 71.91

Panitumumab Plus FOLFIRI 1 0.07 71.98

Panitumumab Plus FOLFOX 1 0.07 72.05

Parenteral Heparin/Oral Vitamin K Ant.. 1 0.07 72.12

Paricalcitol 2 Mcg 1 0.07 72.18

Part 1 Group A: OLE 1 0.07 72.25

Part 1 Group B: Children (0.25 mg/kg .. 1 0.07 72.32

Part 1: Otilimab 90 mg 1 0.07 72.39

Part 1: Placebo 1 1 0.07 72.46

Part 2, DB Period: Venglustat 15 mg 1 0.07 72.53

Part 2: Dexpramipexole (300 mg/Day) 1 0.07 72.60

Part 2: Inclisiran 1 0.07 72.66

Part 2: Otilimab 90 mg 1 0.07 72.73

Part 2: Pembrolizumab + Chemotherapy .. 1 0.07 72.80

Part 2: Placebo 2 1 0.07 72.87

Part A: Remdesivir (RDV) for 5 Days 1 0.07 72.94

Part B: Extension Treatment, Remdesiv.. 1 0.07 73.01

Part B: Placebo Matched to Suptavumab 1 0.07 73.08

Part B: Remdesivir for 10 Days (Exten.. 1 0.07 73.15

Part B: Remdesivir for 10 Days (Mecha.. 1 0.07 73.21

Part B: SAR 200 mg q2w (Cohort 1[Sele.. 1 0.07 73.28

Part C: ECT Food Effect 1 0.07 73.35

Participants Receiving Feladilimab an.. 1 0.07 73.42

Patient Advocate 1 0.07 73.49

Pazopanib 1 0.07 73.56

Pegilodecakin + Pembrolizumab 1 0.07 73.63

Pem + Carb or Cis (Non-Squamous) 1 0.07 73.70

Pembrolizumab + Chemotherapy + Epacad.. 1 0.07 73.76

Pembrolizumab + Lenalidomide + Dexame.. 1 0.07 73.83

Pembrolizumab + SOC 1 0.07 73.90

Pembrolizumab + ST Chemotherapy (Pemb.. 1 0.07 73.97

Pembrolizumab First Course 1 0.07 74.04

Pembrolizumab Monotherapy (Pembro Mono) 1 0.07 74.11

Pemetrexed 1 0.07 74.18

Pemetrexed + Cisplatin - Induction Ph.. 1 0.07 74.24

Pemetrexed + Cisplatin Followed by Pl.. 1 0.07 74.31

Pemetrexed + Enzastaurin 1 0.07 74.38

Pemetrexed + Erlotinib 1 0.07 74.45

Pemetrexed + Erlotinib (Nonsquamous a.. 1 0.07 74.52

Pemetrexed Cisplatin Cetuximab 1 0.07 74.59

Pemetrexed, Gemcitabine, and Bevacizu.. 1 0.07 74.66

Pemetrexed/Carboplatin 1 0.07 74.73

Pemetrexed/Cisplatin 1 0.07 74.79

PerClot 1 0.07 74.86

Percutaneous Coronary Intervention (P.. 1 0.07 74.93

Period 1+2: Upadacitinib 30 mg 1 0.07 75.00

Period II: SerostimÂ® 4 mg to Placebo.. 1 0.07 75.07

Pevonedistat 20 mg/m^2 + Azacitidine .. 1 0.07 75.14

Phase 1: Orteronel 200 mg BID + Docet.. 1 0.07 75.21

Phase 2 Arm D-M20 mg/kg (Q4W) + T1 mg.. 1 0.07 75.27

Phase 2 Cohort 1: Placebo IV 1 0.07 75.34

Phase 2 Cohort 3: Placebo IV 1 0.07 75.41

Phase 2 Unfit: LDAC Alone 1 0.07 75.48

Phase 2: Olaratumab + Nab-paclitaxel .. 1 0.07 75.55

Phase 2: Placebo 1 0.07 75.62

Phase 2: Placebo + Erlotinib 1 0.07 75.69

Phase 2: Pomalidomide (Overall) 1 0.07 75.76

Phase 2: Pomalidomide (Pom + Dex Only) 1 0.07 75.82

Phase 2: Romidepsin 14mg/m^2 1 0.07 75.89

Phase 2: Sarilumab 200mg IV 1 0.07 75.96

Phase 2: Sarilumab 400mg IV 1 0.07 76.03

Phase 2: U3-1287 18 mg/kg + Erlotinib 1 0.07 76.10

Phase 2: U3-1287 9 mg/kg + Erlotinib 1 0.07 76.17

Phase 2: Veliparib + Carboplatin/Etop.. 1 0.07 76.24

Phase 3 Cohort 1: Placebo - Critical 1 0.07 76.30

Phase 3 Cohort 1: Placebo - Severe 1 0.07 76.37

Phase 3 Cohort 1: Placebo IV 1 0.07 76.44

Phase 3 Cohort 1: R10933+R10987 2400m.. 1 0.07 76.51

Phase 3 Cohort 1: R10933+R10987 8000m.. 1 0.07 76.58

Phase 3 Cohort 1: Sarilumab 200 mg IV.. 1 0.07 76.65

Phase 3 Cohort 1: Sarilumab 200mg IV .. 1 0.07 76.72

Phase 3 Cohort 1: Sarilumab 400 mg IV.. 1 0.07 76.79

Phase 3 Cohort 1: Sarilumab 400mg IV .. 1 0.07 76.85

Phase 3 Cohort 1: Sarilumab 400mg IV .. 1 0.07 76.92

Phase 3 Cohort 2: Sarilumab 800 mg IV 1 0.07 76.99

Phase 3: Placebo For 350 mg Bamlanivi.. 1 0.07 77.06

Photodynamic Bone Stabilization Syste.. 1 0.07 77.13

Physician's Choice 2 (PV >=5) 1 0.07 77.20

Pirfenidone+Placebo 1 0.07 77.27

Placebo (0.9% Sodium Chloride Solution) 1 0.07 77.34

Placebo (Overall Cardiovascular Study) 1 0.07 77.40

Placebo (Pioglitazone) 1 0.07 77.47

Placebo (Placebo) 1 0.07 77.54

Placebo (TRANSCEND) 1 0.07 77.61

Placebo (Treatment Period) 1 0.07 77.68

Placebo + ASA 1 0.07 77.75

Placebo + Androgen Deprivation Therapy 1 0.07 77.82

Placebo + Atezolizumab 1 0.07 77.88

Placebo + Everolimus 1 0.07 77.95

Placebo + GEM 1 0.07 78.02

Placebo + Granisetron + Dexamethasone 1 0.07 78.09

Placebo + Letrozole 2.5 mg 1 0.07 78.16

Placebo + Metformin 1 0.07 78.23

Placebo + Paclitaxel/ Carboplatin 1 0.07 78.30

Placebo + Pembrolizumab 1 0.07 78.37

Placebo + Prednisone 5 mg 1 0.07 78.43

Placebo + RT+Temozolomide 1 0.07 78.50

Placebo + Radiotherapy 1 0.07 78.57

Placebo + SOC 1 0.07 78.64

Placebo + SOC CRT 1 0.07 78.71

Placebo + SOC Chemotherapy (SOC) 1 0.07 78.78

Placebo + SoC 1 0.07 78.85

Placebo + Standard of Care 1 0.07 78.91

Placebo + Supportive Care 1 0.07 78.98

Placebo + mFOLFOX6 1 0.07 79.05

Placebo - Low Stratum 1 0.07 79.12

Placebo 0.5 mg 1 0.07 79.19

Placebo 1200mg 1 0.07 79.26

Placebo BID 1 0.07 79.33

Placebo Bid + Symbicort 'as Needed' (.. 1 0.07 79.40

Placebo Comparator 1 0.07 79.46

Placebo Follow-up 1 0.07 79.53

Placebo Plus Best Supportive Care 1 0.07 79.60

Placebo Plus Dexamethasone 1 0.07 79.67

Placebo Plus Docetaxel 1 0.07 79.74

Placebo Plus Metformin 1 0.07 79.81

Placebo Plus Pemetrexed 1 0.07 79.88

Placebo Q6M 1 0.07 79.95

Placebo Safety Set 1 0.07 80.01

Placebo Tablets 1 0.07 80.08

Placebo Tablets of CF102 1 0.07 80.15

Placebo Treatment 1 0.07 80.22

Placebo and 60-mg Prasugrel 1 0.07 80.29

Placebo and Cytarabine 1 0.07 80.36

Placebo and Erlotinib 1 0.07 80.43

Placebo and Prednisone 1 0.07 80.49

Placebo for Levosimendan 1 0.07 80.56

Placebo to Aclidinium Bromide 400 Î¼g.. 1 0.07 80.63

Placebo to Omarigliptin (Phase A) 1 0.07 80.70

Placebo to Omarigliptin (Phase A) â.. 1 0.07 80.77

Placebo+Antiviral Therapy: DB Phase 1 0.07 80.84

Placebo+SOC 1 0.07 80.91

Placebo, Blunt Trauma 1 0.07 80.98

Placebo, Then Tocilizumab Open Label 1 0.07 81.04

Placebo-HM 1 0.07 81.11

Placebo-Period 1 1 0.07 81.18

Placebo-Riociguat Transition 1 0.07 81.25

Placebo-STM 1 0.07 81.32

Placebo/ Ixe 80 mg Q2W - Extended Tre.. 1 0.07 81.39

Placebo/ Pioglitazone 1 0.07 81.46

Placebo/AZLI 1 0.07 81.52

Placebo/Cisplatin 1 0.07 81.59

Placebo/Ipilimumab+ Paclitaxel/Carbop.. 1 0.07 81.66

Placebo/Sitagliptin (Baseline Through.. 1 0.07 81.73

Placebo: Arm B - Control 1 0.07 81.80

Placebo: Conventional Liquid Bicarbon.. 1 0.07 81.87

Placebo: DB Phase 1 0.07 81.94

Placebo: Double-Blind Phase 1 0.07 82.01

Placebo: Double-blind Phase 1 0.07 82.07

Placebo: Double-blind Phase(May 25, 2.. 1 0.07 82.14

Placebo\_Phase III 1 0.07 82.21

Plazomicin in Combination With Merope.. 1 0.07 82.28

Pomalidomide Plus Low-Dose Dexamethas.. 1 0.07 82.35

Post Dabigatran 1 0.07 82.42

Post-discharge 1 0.07 82.49

Pradaxa, Never Randomized 1 0.07 82.55

Pravastatin Group 1 0.07 82.62

Praziquantel at 12-16 Weeks Gestation 1 0.07 82.69

Pre-Frail-HZ/su 1 0.07 82.76

Pre-Frail-Placebo 1 0.07 82.83

Pre-discharge 1 0.07 82.90

Pre-emptive CMV Therapy 1 0.07 82.97

Pre-emptive Skin Treatment 1 0.07 83.04

Pregabalin 600 mg/Day 1 0.07 83.10

Prevnar 13â¢ 1 0.07 83.17

Primary PCI (Group B) 1 0.07 83.24

Prograf (Tacrolimus) 1 0.07 83.31

Prophylaxis 1 0.07 83.38

QVA149 1 0.07 83.45

R-CHOP 1 0.07 83.52

R-CHOP and Enzastaurin 1 0.07 83.59

RAD001 1 0.07 83.65

RAD001 (Everolimus) Active Therapy 1 0.07 83.72

RC: Erlotinib 1 0.07 83.79

REGN910-3 6 mg:2 mg 1 0.07 83.86

RG2: Warfarin DB Period 1 0.07 83.93

RG3: Rivaroxaban Follow-up (FU) Period 1 0.07 84.00

RISPERDAL CONSTA 1 0.07 84.07

RO0503821 (1x/4 Weeks) 1 0.07 84.13

ROSUVASTATIN 20 MG 1 0.07 84.20

RP2D Cohort: ALK-Negative Cohort 1, N.. 1 0.07 84.27

RP2D Cohort: MET Exon 14 Alterations .. 1 0.07 84.34

RT+Cisplatin+Cetuximab 1 0.07 84.41

RVT-101 Treatment 1 0.07 84.48

Radium-223 Dichloride + Abi/Pred 1 0.07 84.55

Ram + Gem + Carb or Cis (Squamous) 1 0.07 84.62

Ramipril (ONTARGET) 1 0.07 84.68

Randomized Sibutramine 1 0.07 84.75

Ranibizumab 0.1 mg 1 0.07 84.82

Ranibizumab 0.5 mg - Months 0-36 1 0.07 84.89

Ranibizumab 0.5mg Q4 1 0.07 84.96

Ranolazine 1 0.07 85.03

Rasburicase 1 0.07 85.10

Relamorelin 30 Î¼g 1 0.07 85.16

Relapser & Partial: Faldaprevir 24 We.. 1 0.07 85.23

Reltecimod (AB103) 0.5 mg/kg 1 0.07 85.30

Remdesivir 1 0.07 85.37

Remdesivir + Placebo (RDV+PBO) 1 0.07 85.44

Remdesivir + Tocilizumab (RDV+TCZ) 1 0.07 85.51

Remdesivir Plus Placebo 1 0.07 85.58

Right Ventricular Pacing Arm 1 0.07 85.65

Riociguat (Adempas, BAY63-2521)\_indiv.. 1 0.07 85.71

Riociguat up to 2.5 mg Tid 1 0.07 85.78

Risperidone 1 0.07 85.85

Rituximab 1 0.07 85.92

Rivaroxaban 10 mg Once Daily (OD) (Xa.. 1 0.07 85.99

Rivaroxaban 10 mg or 7.5 mg 1 0.07 86.06

Rivaroxaban 2.5 mg Bid 1 0.07 86.13

Rivaroxaban 2.5 mg Bid + Aspirin 100 .. 1 0.07 86.20

Rivaroxaban 2.5mg + Aspirin 100mg 1 0.07 86.26

Rivaroxaban 5 mg Bid 1 0.07 86.33

Rivaroxaban 5mg + Aspirin Placebo 1 0.07 86.40

Rivaroxaban Arm 1 0.07 86.47

Rolapitant + Granisetron + Dexamethas.. 1 0.07 86.54

RotaTeqâ¢ 1 0.07 86.61

Routine Vaccines 1 0.07 86.68

Rovalpituzumab Tesirine 1 0.07 86.74

Ruboxistaurin 1 0.07 86.81

Ruxolitinib 1 0.07 86.88

Ruxolitinib Plus Capecitabine 1 0.07 86.95

Ryanodex 1 0.07 87.02

S-649266 1 0.07 87.09

SAGE-547 1 0.07 87.16

SAL 50 1 0.07 87.23

SAR342434 1 0.07 87.29

SAR440340 1 0.07 87.36

SD-809 36 mg/Day 1 0.07 87.43

SFP in Liquid Bicarbonate 1 0.07 87.50

SGI-110 (Guadecitabine) 1 0.07 87.57

SNF472 1 0.07 87.64

SOC Chemotherapy First Course 1 0.07 87.71

SU011248 1 0.07 87.77

SUN-101 50 mcg BID eFlow (CS) Nebulizer 1 0.07 87.84

SURFAXIN Low Dose 1 0.07 87.91

SVd Arm: Selinexor + Bortezomib + Dex.. 1 0.07 87.98

SYN-004 1 0.07 88.05

Safety Run-in Phase: Daratumumab + At.. 1 0.07 88.12

Safinamide 1 0.07 88.19

Saline 1 0.07 88.26

Saline + Placebo 1 0.07 88.32

Salmeterol 1 0.07 88.39

Sarilumab 200 mg 1 0.07 88.46

Sarilumab 400 mg 1 0.07 88.53

Second Extension: Odanacatib 50 mg OW 1 0.07 88.60

Second Extension: Odanacatib 50 mg OW.. 1 0.07 88.67

Selexipag 1 0.07 88.74

Selonsertib 18 mg 1 0.07 88.80

Semaglutide 0.5 mg 1 0.07 88.87

Semaglutide 1.0 mg 1 0.07 88.94

Semaglutide 1.0 mg + Sitagliptin Plac.. 1 0.07 89.01

SenSura 1 0.07 89.08

Sentus QP Left Ventricular Lead 1 0.07 89.15

Serelaxin (RLX030) 1 0.07 89.22

Serelaxin + Standard of Care 1 0.07 89.29

Sertindole 1 0.07 89.35

Sevelamer Carbonate 2.4 g/Day 1 0.07 89.42

Sevoflurane 1 0.07 89.49

Sham + Ranibizumab + Laser 1 0.07 89.56

Sham Injection/Ranibizumab 0.5 mg - M.. 1 0.07 89.63

Sham With Ranibizumab 0.5mg 1 0.07 89.70

Shorter-storage Red Blood Cell Units 1 0.07 89.77

Sifalimumab 600 mg 1 0.07 89.84

Sildenafil 20 mg 1 0.07 89.90

Sildenafil 80 mg 1 0.07 89.97

Sildenafil High Dose 1 0.07 90.04

Simtuzumab 1 0.07 90.11

Single-Agent QW Arm: Sapanisertib 30 mg 1 0.07 90.18

Sipuleucel-T Without Booster 1 0.07 90.25

Sitaxsentan and Sildenafil 1 0.07 90.32

Solanezumab 1 0.07 90.38

Solanezumab: Double-Blind Phase 1 0.07 90.45

Somatropin 1 0.07 90.52

Sorafenib (Second-line Participants) 1 0.07 90.59

Sorafenib+Mapatumumab 30 mg/kg 1 0.07 90.66

Sotagliflozin 400 mg 1 0.07 90.73

Spiriva 18 mcg QD Handihaler 1 0.07 90.80

Stage 1: 1600mg Fluconazole 1 0.07 90.87

Stage 2 Placebo (Standard Dialysate) 1 0.07 90.93

Stage 3 Soluble Ferric Pyrophosphate .. 1 0.07 91.00

Stage 3 Soluble Ferric Pyrophosphate .. 1 0.07 91.07

Standard Balloon Angioplasty 1 0.07 91.14

Standard Biventricular Pacing 1 0.07 91.21

Standard of Care (SOC) 1 0.07 91.28

Staphylococcus Aureus 4-antigen (SA4Ag) 1 0.07 91.35

StioltoÂ® RespimatÂ® 1 0.07 91.41

Study Cohort 1 0.07 91.48

Sub Q Insulin to Keep Glucose Less Th.. 1 0.07 91.55

Subcutaneous Hylenex 1 0.07 91.62

Subjects Assigned to Placebo + Low-do.. 1 0.07 91.69

Subjects Assigned to Volasertib + Low.. 1 0.07 91.76

Sunitinib + Erlotinib 1 0.07 91.83

Sunitinib Open-Label Treatment 1 0.07 91.90

Sunitinib and Prednisone 1 0.07 91.96

Symbicort 160/4.5 ug x2 Bid 1 0.07 92.03

TAS-102 1 0.07 92.10

TAS-102+BSC 1 0.07 92.17

TAS-114 + S-1 1 0.07 92.24

TAXUS Element 1 0.07 92.31

TAXUS Express 1 0.07 92.38

TIO 18 Âµg OD 1 0.07 92.45

TIO18 Âµg QD 1 0.07 92.51

TREMELIMUMAB 1 0.07 92.58

TYRX Envelope 1 0.07 92.65

TachoSilÂ® 1 0.07 92.72

TachoSilÂ® (Adult Participants) 1 0.07 92.79

Tacrolimus MR 1 0.07 92.86

Tacrolimus Modified Release 1 0.07 92.93

Tacrolimus, Extended Release (Astagra.. 1 0.07 92.99

Tacrolimus/MMF/Basiliximab 1 0.07 93.06

Tafamidis 80 mg 1 0.07 93.13

Talazoparib: Severe Hepatic Impairment 1 0.07 93.20

Talimogene Laherparepvec 1 0.07 93.27

Tandem Auto Transplant 1 0.07 93.34

Tanezumab 10 mg + Celecoxib 100 mg 1 0.07 93.41

Tanezumab 5 mg 1 0.07 93.48

Targeted CFAE Ablation 1 0.07 93.54

Tedizolid 1 0.07 93.61

Telmisartan (ONTARGET) 1 0.07 93.68

Telmisartan (TRANSCEND) 1 0.07 93.75

Telmisartan/Ramipril (ONTARGET) 1 0.07 93.82

Temozolomide 1 0.07 93.89

Temsirolimus 1 0.07 93.96

Tenecteplase (Group A) 1 0.07 94.02

Teriparatide 1 0.07 94.09

Teriparatide (During 104 Weeks) 1 0.07 94.16

Teriparatide (During 52 Weeks) 1 0.07 94.23

Teriparatide (During 76 Weeks) 1 0.07 94.30

Terminated Prior to Randomization 1 0.07 94.37

Therapeutic Hypothermia 1 0.07 94.44

Ticagrelor 60 mg 1 0.07 94.51

Ticagrelor 60mg bd 1 0.07 94.57

Ticagrelor 90mg 1 0.07 94.64

Ticagrelor Placebo 1 0.07 94.71

Tildrakizumab 100 mg (Parts 1, 2 & 3) 1 0.07 94.78

Tio+Olo 2.5 / 5.0 Î¼g 1 0.07 94.85

Tio+Olo FDC (2.5/5 Î¼g) 1 0.07 94.92

Tio+Olo FDC (5/5 Î¼g) 1 0.07 94.99

Tiotropium (2.5 Î¼g) 1 0.07 95.05

Tiotropium (5 Î¼g) + Olodaterol (5 Î¼g) 1 0.07 95.12

Tiotropium 18 mcg and Placebo 1 0.07 95.19

Tiotropium 2.5 mcg and Placebo 1 0.07 95.26

Tiotropium 5 Microgram (Î¼g) 1 0.07 95.33

Tiotropium 5 mcg and Placebo 1 0.07 95.40

Tiotropium Bromide Inhalation Capsule.. 1 0.07 95.47

Tiotropium Respimat 5mcg 1 0.07 95.54

Tipranavir(TPV)/Low Dose Ritonavir(r) 1 0.07 95.60

Tivantinib and Erlotinib 1 0.07 95.67

Tivozanib Hydrochloride 1 0.07 95.74

Tocilizumab 1 0.07 95.81

Tocilizumab (TCZ) Arm (Safety-Evaluab.. 1 0.07 95.88

Tofacitinib 10 mg BID 1 0.07 95.95

Tolvaptan 1 0.07 96.02

Topotecan 1 0.07 96.09

Total Participants 1 0.07 96.15

Total: Romidepsin 14mg/m^2 1 0.07 96.22

Toujeo 1 0.07 96.29

Trabectedin 0.58 mg/m2 1 0.07 96.36

Tranexamic Acid Plus Standard of Care 1 0.07 96.43

Trastuzumab + Bevacizumab + Docetaxel 1 0.07 96.50

Trastuzumab+AI 1 0.07 96.57

Treated 1 0.07 96.63

Treatment B 1 0.07 96.70

Treatment C 1 0.07 96.77

Triheptanoin-NaÃ¯ve Cohort 1 0.07 96.84

UMEC 125 Âµg QD + FSC 250/50 Âµg BID 1 0.07 96.91

UMEC 62.5 mcg + Placebo 1 0.07 96.98

UMEC/VI 62.5/25 1 0.07 97.05

UMEC/VI 62.5/25 mcg+ Placebo 1 0.07 97.12

US-licensed Epoetin Alfa 1 0.07 97.18

UST 90 mg SC Q12W LTE 1 0.07 97.25

UT-15C 1 0.07 97.32

UTTR1147A 1 0.07 97.39

UX007-CL201-Rollover Cohort 1 0.07 97.46

Upadacitinib 15 mg 1 0.07 97.53

Upadacitinib 15 mg: Week 1-24 1 0.07 97.60

Upadacitinib 15 mg: Week 1-56 1 0.07 97.66

V212-HM 1 0.07 97.73

V212-STM 1 0.07 97.80

V710 (60 Âµg) Lyophilized 1 0.07 97.87

VAP Treated With Doripenem 1 0.07 97.94

VIABAHN Treatment Group 1 0.07 98.01

VKA With Placebo Matching Acetylsalic.. 1 0.07 98.08

VNS Therapy 1 0.07 98.15

VX-210 9 mg 1 0.07 98.21

Valsartan 1 0.07 98.28

Veliparib + Carboplatin + Paclitaxel 1 0.07 98.35

Vericiguat 1 0.07 98.42

Vertebroplasty 1 0.07 98.49

Vilanterol 25 Âµg 1 0.07 98.56

Vimpat + Non-Na Channel Blocking AED 1 0.07 98.63

Vitamin E 1 0.07 98.70

Vitamin K Antagonist (1) 1 0.07 98.76

Vitamin K Antagonist (VKA) 1 0.07 98.83

Vitamin K Antagonist (VKA) With Acety.. 1 0.07 98.90

Vonapanitase 1 0.07 98.97

Voriconazole / Placebo 1 0.07 99.04

Vorinostat 1 0.07 99.11

Warfarin/Placebo Edoxaban 1 0.07 99.18

XELOX Q2W + Bevacizumab 1 0.07 99.24

XIENCE VÂ® EECSS 1 0.07 99.31

ZenithÂ® TX2Â® Low Profile TAA Endova.. 1 0.07 99.38

Zilucoplan + SoC 1 0.07 99.45

Zoster-022 GSK1437173A Group 1 0.07 99.52

Zoster-022 Placebo Group 1 0.07 99.59

aH5N1c 1 0.07 99.66

aTIV (Pooled) 1 0.07 99.73

dUCB 1 0.07 99.79

mIFL 1 0.07 99.86

rVIIa, Penetrating Trauma 1 0.07 99.93

rhEPO 1 0.07 100.00

And Conditions:  Definitive hypovent

condition       Freq.     Percent Cum.

['Amyotrophic Lateral Sclerosis'] 13 4.19 4.19

['Pulmonary Disease, Chronic Obstruct.. 11 3.55 7.74

['Diabetes Mellitus, Type 2'] 7 2.26 10.00

['Breast Cancer'] 6 1.94 11.94

['Heart Failure'] 5 1.61 13.55

['Acute Coronary Syndrome'] 4 1.29 14.84

['Respiratory Syncytial Virus Infecti.. 4 1.29 16.13

['Arthritis, Rheumatoid'] 3 0.97 17.10

['Bacterial Pneumonia'] 3 0.97 18.06

['Bone Metastases'] 3 0.97 19.03

['COVID-19'] 3 0.97 20.00

['Carcinoma, Non-Small-Cell Lung'] 3 0.97 20.97

['Cardiovascular Diseases'] 3 0.97 21.94

['Cervical Ripening', 'Labor, Induced'] 3 0.97 22.90

['Chronic Obstructive Pulmonary Disea.. 3 0.97 23.87

['Coronavirus Disease (COVID-19)'] 3 0.97 24.84

['Diabetic Macular Edema'] 3 0.97 25.81

['Heart Failure With Preserved Ejecti.. 3 0.97 26.77

['Herpes Zoster'] 3 0.97 27.74

['Moderate to Very Severe Chronic Obs.. 3 0.97 28.71

['Multiple Myeloma'] 3 0.97 29.68

['PNC Vaccine', 'HIV-infected Pregnan.. 3 0.97 30.65

['Venous Thromboembolism'] 3 0.97 31.61

["Glycogen Storage Disease Type II;Po.. 2 0.65 32.26

['Anaemia', 'Aspergillosis, Allergic .. 2 0.65 32.90

['Anemia', 'Dialysis-Dependent Chroni.. 2 0.65 33.55

['Aortic Stenosis'] 2 0.65 34.19

['Aspergillosis', 'Invasive Fungal In.. 2 0.65 34.84

['Atherosclerosis', 'Ischemia', 'Myoc.. 2 0.65 35.48

['Atherosclerosis'] 2 0.65 36.13

['Atherosclerotic Cardiovascular Dise.. 2 0.65 36.77

['COPD Exacerbation'] 2 0.65 37.42

['COPD', 'Chronic Obstructive Pulmona.. 2 0.65 38.06

['Cardiac Arrest'] 2 0.65 38.71

['Cardiovascular Disease', 'High Card.. 2 0.65 39.35

['Chronic Obstructive Pulmonary Disea.. 2 0.65 40.00

['Congenital Heart Disease'] 2 0.65 40.65

['Coronary Arteriosclerosis', 'Acute .. 2 0.65 41.29

['Coronary Artery Disease'] 2 0.65 41.94

['Deep Vein Thrombosis', 'Pulmonary E.. 2 0.65 42.58

['Diabetes Mellitus, Non-Insulin-Depe.. 2 0.65 43.23

['Diabetes Mellitus, Type 2', 'Albumi.. 2 0.65 43.87

['HIV Infections'] 2 0.65 44.52

['Heart Failure', 'Anemia', 'Cardiova.. 2 0.65 45.16

['Hemostasis'] 2 0.65 45.81

['Infections, Streptococcal'] 2 0.65 46.45

['Lung Cancer'] 2 0.65 47.10

['Melanoma'] 2 0.65 47.74

['Methicillin Resistant Staphylococcu.. 2 0.65 48.39

['Non-Small Cell Lung Cancer', 'Anemi.. 2 0.65 49.03

['Nonproliferative Diabetic Retinopat.. 2 0.65 49.68

['Pancreatic Cancer'] 2 0.65 50.32

['Post Operative Pain'] 2 0.65 50.97

['Postmenopausal Women With Osteoporo.. 2 0.65 51.61

['Prostatic Hyperplasia'] 2 0.65 52.26

['Psoriasis'] 2 0.65 52.90

['Respiratory Distress Syndrome, Newb.. 2 0.65 53.55

['Respiratory Tract Infection'] 2 0.65 54.19

['Rotavirus Infections'] 2 0.65 54.84

['Secondary Hyperparathyroidism', 'Ch.. 2 0.65 55.48

['Severe Acute Respiratory Syndrome'] 2 0.65 56.13

['Small Cell Lung Carcinoma'] 2 0.65 56.77

['Spinal Muscular Atrophy'] 2 0.65 57.42

['Sternal Wound Infection', 'Sternal .. 2 0.65 58.06

['Stroke', 'Atrial Fibrillation', 'Em.. 2 0.65 58.71

['Ureaplasma Infections'] 2 0.65 59.35

['Vaccines, Pneumococcal'] 2 0.65 60.00

["Alzheimer's Disease"] 1 0.32 60.32

['Acquired Bleeding Disorder', 'Traum.. 1 0.32 60.65

['Acute Heart Failure'] 1 0.32 60.97

['Acute Lymphoblastic Leukemia', 'Chi.. 1 0.32 61.29

['Acute Pain Following a Total Abdomi.. 1 0.32 61.61

['Acute Pain'] 1 0.32 61.94

['Anaemia'] 1 0.32 62.26

['Anemia', 'Non-Dialysis-Dependent Ch.. 1 0.32 62.58

['Anemia'] 1 0.32 62.90

['Arthroplasty, Replacement, Knee', '.. 1 0.32 63.23

['Arthroplasty, Replacement, Knee'] 1 0.32 63.55

['Aspergillosis'] 1 0.32 63.87

['Asthma'] 1 0.32 64.19

['Atherosclerosis', 'Myocardial Ische.. 1 0.32 64.52

['Atrial Fibrillation', 'Stroke'] 1 0.32 64.84

['Atrial Fibrillation', 'Vascular Ris.. 1 0.32 65.16

['Atrial Fibrillation'] 1 0.32 65.48

['Attention Deficit Hyperactivity Dis.. 1 0.32 65.81

['Back Pain Lower Back Chronic'] 1 0.32 66.13

['Bloodloss', 'Surgical Procedures, O.. 1 0.32 66.45

['Breast Adenocarcinoma'] 1 0.32 66.77

['Breast Neoplasms'] 1 0.32 67.10

['COPD', 'COPD Exacerbation', 'Lung D.. 1 0.32 67.42

['COPD'] 1 0.32 67.74

['COVID-19 Pneumonia'] 1 0.32 68.06

['Cancer', 'Hematologic Malignancies'.. 1 0.32 68.39

['Candidiasis, Invasive'] 1 0.32 68.71

['Carcinoma', 'Non-Small-Cell Lung'] 1 0.32 69.03

['Carcinoma, Hepatocellular'] 1 0.32 69.35

['Cardiac Surgery', 'Cardiopulmonary .. 1 0.32 69.68

['Cardiovascular Disease', 'Diabetes .. 1 0.32 70.00

['Cardiovascular Disease'] 1 0.32 70.32

['Cardiovascular Diseases', 'Heart Di.. 1 0.32 70.65

['Chronic Kidney Disease', 'End-Stage.. 1 0.32 70.97

['Chronic Kidney Disease'] 1 0.32 71.29

['Chronic Renal Failure', 'Chronic Ki.. 1 0.32 71.61

['Clostridium Difficile Infection'] 1 0.32 71.94

['Colorectal Neoplasms'] 1 0.32 72.26

['Corona Virus Infection', 'ARDS', 'A.. 1 0.32 72.58

['Cryptogenic Stroke'] 1 0.32 72.90

['Current or Recent History of Atrial.. 1 0.32 73.23

['Diabetes Mellitus'] 1 0.32 73.55

['Diabetes Mellitus, Type 2', 'Cardio.. 1 0.32 73.87

['Diabetes Mellitus, Type 2', 'Diabet.. 1 0.32 74.19

['Diabetes', 'Diabetes Mellitus, Type.. 1 0.32 74.52

['Diabetic Kidney Disease'] 1 0.32 74.84

['Diabetic Retinopathy'] 1 0.32 75.16

['Dyslipidemia'] 1 0.32 75.48

['Elevated High-sensitivity C-Reactiv.. 1 0.32 75.81

['Eligible Men or Women Considered Hi.. 1 0.32 76.13

['Endometrial Cancer'] 1 0.32 76.45

['Epilepsy', 'Dravet Syndrome'] 1 0.32 76.77

['Epilepsy', 'Lennox Gastaut Syndrome'] 1 0.32 77.10

['Epilepsy', 'Lennox-Gastaut Syndrome'] 1 0.32 77.42

['Genital Neoplasms, Female', 'Fallop.. 1 0.32 77.74

['Graft Versus Host Disease', 'Hemato.. 1 0.32 78.06

['HIV', 'HIV Infections'] 1 0.32 78.39

['Haemophilus Influenzae Type b', 'Ne.. 1 0.32 78.71

['Head and Neck Neoplasms', 'Carcinom.. 1 0.32 79.03

['Heart Defects, Congenital'] 1 0.32 79.35

['Heart Failure', 'Type 2 Diabetes Me.. 1 0.32 79.68

['Hepatitis C'] 1 0.32 80.00

['Hypercholesterolemia', 'Myocardial .. 1 0.32 80.32

['Hyperparathyroidism, Secondary'] 1 0.32 80.65

['Hyponatremia'] 1 0.32 80.97

['Idiopathic Pulmonary Fibrosis'] 1 0.32 81.29

['Infection'] 1 0.32 81.61

['Infections, Streptococcal', 'Strept.. 1 0.32 81.94

['Kidney Neoplasms'] 1 0.32 82.26

['Kidney Transplantation'] 1 0.32 82.58

['Liver Fibrosis', 'Nonalcoholic Fatt.. 1 0.32 82.90

['Localized Resectable Neuroblastoma'.. 1 0.32 83.23

['Lung Cancer - Non Small Cell Squamo.. 1 0.32 83.55

['Lung Cancer, Non-Small Cell'] 1 0.32 83.87

['Macular Edema Secondary to Central .. 1 0.32 84.19

['Malaria'] 1 0.32 84.52

['Measles', 'Mumps', 'Rubella', 'Meas.. 1 0.32 84.84

['Melanoma', 'Metastases'] 1 0.32 85.16

['Meningococcal Infections'] 1 0.32 85.48

['Mesothelioma', 'Lung Cancer'] 1 0.32 85.81

['Metastatic Colorectal Cancer'] 1 0.32 86.13

['Migraine Disorders'] 1 0.32 86.45

['Migraine'] 1 0.32 86.77

['Myocardial Infarction', 'Cardiovasc.. 1 0.32 87.10

['Nausea', 'Vomiting'] 1 0.32 87.42

['Neoplasms, Prostate'] 1 0.32 87.74

['Non Small Cell Lung Cancer (NSCLC)'] 1 0.32 88.06

['Non-Small-Cell Lung Carcinoma NSCLC'] 1 0.32 88.39

['Non-small Cell Lung Cancer'] 1 0.32 88.71

['Obesity'] 1 0.32 89.03

['Osteoarthritis', 'Postoperative Pai.. 1 0.32 89.35

['Persistent Pulmonary Hypertension o.. 1 0.32 89.68

['Pneumococcal Infections'] 1 0.32 90.00

['Pneumonia'] 1 0.32 90.32

['Pneumonia, Bacterial'] 1 0.32 90.65

['Post-Operative Pain'] 1 0.32 90.97

['Postoperative Nausea and Vomiting'] 1 0.32 91.29

['Postoperative Pain', 'Abdominal Sur.. 1 0.32 91.61

['Postoperative Pain'] 1 0.32 91.94

['Prevention & Control'] 1 0.32 92.26

['Prostate Cancer'] 1 0.32 92.58

['Pseudobulbar Affect (PBA)'] 1 0.32 92.90

['Pulmonary Arterial Hypertension'] 1 0.32 93.23

['Pulmonary Fibrosis'] 1 0.32 93.55

['Pulmonary Hypertension, Familial Pe.. 1 0.32 93.87

['Recurrent and/or Metastatic Head an.. 1 0.32 94.19

['Recurrent or Metastatic PD-L1-posit.. 1 0.32 94.52

['Reducing Time to Vaginal Delivery',.. 1 0.32 94.84

['Refractory Generalized Myasthenia G.. 1 0.32 95.16

['Retinopathy of Prematurity (ROP)'] 1 0.32 95.48

['SARS-CoV 2'] 1 0.32 95.81

['Secondary Progressive Multiple Scle.. 1 0.32 96.13

['Serogroup B Meningococcal Meningiti.. 1 0.32 96.45

['Sickle Cell Anemia', 'Sickle Ã0-Th.. 1 0.32 96.77

['Stress Ulcer Prophylaxis'] 1 0.32 97.10

['Stroke'] 1 0.32 97.42

['Supranuclear Palsy, Progressive'] 1 0.32 97.74

['Surgical Site Occurences After Ster.. 1 0.32 98.06

['Thromboembolism', 'Arthroplasty, Re.. 1 0.32 98.39

['Transthyretin (TTR) Amyloid Cardiom.. 1 0.32 98.71

['Type 2 Diabetes Mellitus'] 1 0.32 99.03

['Urinary Bladder Overactive', 'Urina.. 1 0.32 99.35

['Venous Leg Ulcers', 'Diabetic Foot .. 1 0.32 99.68

['Ventilator-Associated Pneumonia'] 1 0.32 100.00

Total 310 100.00

Pos Hypovent

condition Freq. Percent Cum.

['Pulmonary Disease, Chronic Obstruct.. 27 2.81 2.81

['Diabetes Mellitus, Type 2'] 23 2.40 5.21

['COVID-19'] 16 1.67 6.88

['Diabetes', 'Diabetes Mellitus, Type.. 15 1.56 8.44

["Alzheimer's Disease"] 14 1.46 9.90

['Breast Cancer'] 13 1.35 11.25

['Carcinoma, Non-Small-Cell Lung'] 12 1.25 12.50

['Type 2 Diabetes Mellitus'] 12 1.25 13.75

['Acute Coronary Syndrome'] 11 1.15 14.90

['Non-Small Cell Lung Cancer'] 11 1.15 16.04

['Non-small Cell Lung Cancer'] 11 1.15 17.19

['Chronic Renal Failure', 'Chronic Ki.. 10 1.04 18.23

['Prostate Cancer'] 10 1.04 19.27

['Anemia'] 9 0.94 20.21

['Atrial Fibrillation'] 9 0.94 21.15

['Multiple Myeloma'] 9 0.94 22.08

['Postmenopausal Osteoporosis'] 9 0.94 23.02

['Pulmonary Arterial Hypertension'] 9 0.94 23.96

['Clostridium Difficile Infection'] 8 0.83 24.79

['Heart Failure'] 8 0.83 25.62

['Amyotrophic Lateral Sclerosis'] 7 0.73 26.35

['Atherosclerosis'] 7 0.73 27.08

['Idiopathic Pulmonary Fibrosis'] 7 0.73 27.81

['Bacterial Pneumonia'] 6 0.62 28.44

['Bone Metastases'] 6 0.62 29.06

['COVID-19 Pneumonia'] 6 0.62 29.69

['Colorectal Cancer'] 6 0.62 30.31

['Herpes Zoster'] 6 0.62 30.94

['Rheumatoid Arthritis'] 6 0.62 31.56

['Asthma'] 5 0.52 32.08

['Chronic Kidney Disease'] 5 0.52 32.60

['Chronic Obstructive Pulmonary Disea.. 5 0.52 33.13

['Heart Failure With Preserved Ejecti.. 5 0.52 33.65

['Moderate to Very Severe Chronic Obs.. 5 0.52 34.17

['Prostatic Neoplasms'] 5 0.52 34.69

['Squamous Cell Carcinoma of the Head.. 5 0.52 35.21

['Anemia', 'Non-Dialysis-Dependent Ch.. 4 0.42 35.63

['Arthritis, Rheumatoid'] 4 0.42 36.04

['Coronary Artery Disease'] 4 0.42 36.46

['Covid19'] 4 0.42 36.88

['Diabetic Macular Edema'] 4 0.42 37.29

['Gastric Adenocarcinoma'] 4 0.42 37.71

['Head and Neck Neoplasms'] 4 0.42 38.12

['Hepatitis C, Chronic'] 4 0.42 38.54

['Non Small Cell Lung Cancer'] 4 0.42 38.96

['Renal Cell Carcinoma'] 4 0.42 39.37

['Severe Acute Respiratory Syndrome'] 4 0.42 39.79

['Small Cell Lung Cancer'] 4 0.42 40.21

['Acute Ischaemic Stroke', 'Transient.. 3 0.31 40.52

['Anaemia'] 3 0.31 40.83

['Anemia', 'Dialysis-Dependent Chroni.. 3 0.31 41.15

['Aortic Stenosis'] 3 0.31 41.46

['Atrioventricular Block', 'Heart Dis.. 3 0.31 41.77

['Breast Neoplasms'] 3 0.31 42.08

['COVID-19 Pneumonia, Impaired Respir.. 3 0.31 42.40

['Carcinoma, Renal Cell'] 3 0.31 42.71

['Cardiovascular Disease'] 3 0.31 43.02

['Cardiovascular Diseases'] 3 0.31 43.33

['Chronic Obstructive Pulmonary Disea.. 3 0.31 43.65

['Coronary Artery Disease', 'Coronary.. 3 0.31 43.96

['Diabetes Mellitus, Type 2', 'Cardio.. 3 0.31 44.27

['Diabetic Kidney Disease'] 3 0.31 44.58

['Gastric Cancer', 'Gastroesophageal .. 3 0.31 44.90

['Gastric Cancer'] 3 0.31 45.21

['Kidney Transplantation', 'Chronic K.. 3 0.31 45.52

['Kidney Transplantation'] 3 0.31 45.83

['Leukemia, Myeloid, Acute'] 3 0.31 46.15

['Malaria'] 3 0.31 46.46

['Metastatic Colorectal Cancer'] 3 0.31 46.77

['Myocardial Infarction', 'Cardiovasc.. 3 0.31 47.08

['NSCLC (Advanced Non-small Cell Lung.. 3 0.31 47.40

['Neoplasms, Breast'] 3 0.31 47.71

['Neoplasms, Prostate'] 3 0.31 48.02

['Obesity'] 3 0.31 48.33

['Osteoporosis'] 3 0.31 48.65

['Peripheral Artery Disease'] 3 0.31 48.96

['Postmenopausal Women With Osteoporo.. 3 0.31 49.27

['Pulmonary Hypertension'] 3 0.31 49.58

['Renal Transplantation'] 3 0.31 49.90

['Secondary Hyperparathyroidism', 'Ch.. 3 0.31 50.21

['Sepsis'] 3 0.31 50.52

['Small-cell Lung Cancer'] 3 0.31 50.83

['Stroke', 'Atrial Fibrillation', 'Em.. 3 0.31 51.15

['Systemic Lupus Erythematosus'] 3 0.31 51.46

['Venous Thromboembolism'] 3 0.31 51.77

['Venous Thrombosis'] 3 0.31 52.08

["Non-Hodgkin's Lymphoma"] 2 0.21 52.29

['Acquired Bleeding Disorder', 'Traum.. 2 0.21 52.50

['Acute Coronary Syndrome', 'Myocardi.. 2 0.21 52.71

['Acute Heart Failure'] 2 0.21 52.92

['Acute Ischemic Stroke', 'Diabetes',.. 2 0.21 53.12

['Acute Kidney Injury'] 2 0.21 53.33

['AlzheimerÂ´s Disease'] 2 0.21 53.54

['Anaemia', 'Aspergillosis, Allergic .. 2 0.21 53.75

['Anemia in Chronic Kidney Disease in.. 2 0.21 53.96

['Anemia in Incident Dialysis Patient.. 2 0.21 54.17

['Anemia', 'Chronic Kidney Disease (C.. 2 0.21 54.38

['Anemia', 'End Stage Renal Disease (.. 2 0.21 54.58

['Arteriovenous Fistula Stenosis', 'A.. 2 0.21 54.79

['Aspergillosis', 'Invasive Fungal In.. 2 0.21 55.00

['Atherosclerosis', 'Ischemia', 'Myoc.. 2 0.21 55.21

['Atherosclerosis', 'Myocardial Ische.. 2 0.21 55.42

['Atherosclerotic Cardiovascular Dise.. 2 0.21 55.63

['Atopic Dermatitis'] 2 0.21 55.83

['Atrial Fibrillation', 'Atrial Flutt.. 2 0.21 56.04

['Atrial Fibrillation', 'Cardiovascul.. 2 0.21 56.25

['Atrial Fibrillation', 'Stroke', 'Em.. 2 0.21 56.46

['Bladder Cancer'] 2 0.21 56.67

['Breast Cancer', 'Metastases'] 2 0.21 56.88

['Bronchopulmonary Dysplasia'] 2 0.21 57.08

['CKD Anemia in Stable Dialysis Patie.. 2 0.21 57.29

['CKD Anemia'] 2 0.21 57.50

['COPD', 'COPD Exacerbation', 'Lung D.. 2 0.21 57.71

['COVID-19', 'SARS-CoV2'] 2 0.21 57.92

['Cancer', 'Breast Cancer'] 2 0.21 58.13

['Cancer', 'Cataract', 'Low Bone Mine.. 2 0.21 58.33

['Cancer', 'Hematologic Malignancies'.. 2 0.21 58.54

['Candidiasis, Invasive', 'Candidemia.. 2 0.21 58.75

['Carcinoma, Basal Cell', 'Carcinoma,.. 2 0.21 58.96

['Carcinoma, Squamous Cell', 'Carcino.. 2 0.21 59.17

['Cardiovascular Disease', 'Diabetes .. 2 0.21 59.38

['Cardiovascular Disease', 'High Card.. 2 0.21 59.58

['Catecholamine-resistant Hypotension.. 2 0.21 59.79

['Cerebrovascular Accident'] 2 0.21 60.00

['Chemotherapy-Induced Nausea and Vom.. 2 0.21 60.21

['Chemotherapy-induced Nausea and Vom.. 2 0.21 60.42

['Chronic Kidney Disease', 'Chronic R.. 2 0.21 60.63

['Chronic Kidney Disease', 'End-Stage.. 2 0.21 60.83

['Clostridium Infections', 'Diarrhea'] 2 0.21 61.04

['Congenital Heart Disease'] 2 0.21 61.25

['Corona Virus Infection'] 2 0.21 61.46

['Coronary Arteriosclerosis', 'Acute .. 2 0.21 61.67

['Coronary Artery Disease', 'Angina P.. 2 0.21 61.88

['Coronavirus Disease 2019 (COVID-19)'] 2 0.21 62.08

['Critical Limb Ischemia'] 2 0.21 62.29

['Cytomegalovirus (CMV)-Positive Reci.. 2 0.21 62.50

['Cytomegalovirus Infections'] 2 0.21 62.71

['Diabetes Mellitus', 'Macular Edema'] 2 0.21 62.92

['Diabetes Mellitus'] 2 0.21 63.13

['Diabetes Mellitus, Non-Insulin-Depe.. 2 0.21 63.33

['Diabetes Mellitus, Type 2', 'Albumi.. 2 0.21 63.54

['Diabetes Mellitus, Type 2', 'Diabet.. 2 0.21 63.75

['Diabetic Retinopathy'] 2 0.21 63.96

['Dyslipidemia'] 2 0.21 64.17

['Elevated High-sensitivity C-Reactiv.. 2 0.21 64.38

['Head and Neck Cancer'] 2 0.21 64.58

['Healthcare-Associated Pneumonia', '.. 2 0.21 64.79

['Healthcare-associated Pneumonia (HC.. 2 0.21 65.00

['Heart Defects, Congenital'] 2 0.21 65.21

['Heart Failure', 'Anemia', 'Cardiova.. 2 0.21 65.42

['Heart Failure', 'Chronic Heart Fail.. 2 0.21 65.63

['Heart Failure', 'Respiratory Insuff.. 2 0.21 65.83

['Heart Failure', 'Type 2 Diabetes Me.. 2 0.21 66.04

['Hepatocellular Carcinoma'] 2 0.21 66.25

['Herpes Zoster', 'Herpes Zoster Vacc.. 2 0.21 66.46

['Hypercholesterolemia', 'Myocardial .. 2 0.21 66.67

['Hypercholesterolemia'] 2 0.21 66.88

['Infection'] 2 0.21 67.08

['Kidney Failure, Chronic', 'Catheter.. 2 0.21 67.29

['Kidney Neoplasms'] 2 0.21 67.50

['Leukaemia, Lymphocytic, Chronic'] 2 0.21 67.71

['Lung Cancer - Non Small Cell Squamo.. 2 0.21 67.92

['Lung Diseases, Interstitial'] 2 0.21 68.13

['Lymphoma, Follicular'] 2 0.21 68.33

['Macular Degeneration'] 2 0.21 68.54

['Mantle Cell Lymphoma'] 2 0.21 68.75

['Melanoma'] 2 0.21 68.96

['Mesothelioma'] 2 0.21 69.17

['Metabolism and Nutrition Disorder',.. 2 0.21 69.38

['Metastatic Hormone Sensitive Prosta.. 2 0.21 69.58

['Metastatic Pancreatic Cancer'] 2 0.21 69.79

['Methicillin Resistant Staphylococcu.. 2 0.21 70.00

['Moderate to Severe Plaque-type Psor.. 2 0.21 70.21

['Myelodysplastic Syndromes'] 2 0.21 70.42

['Neoplasms, Head and Neck'] 2 0.21 70.62

['Neovascular Age-Related Macular Deg.. 2 0.21 70.83

['Non Small Cell Lung Cancer (NSCLC)'] 2 0.21 71.04

['Non Squamous, Non-small-cell Lung C.. 2 0.21 71.25

['Non-Small Cell Lung Cancer', 'Anemi.. 2 0.21 71.46

['Non-Small Cell Lung Carcinoma'] 2 0.21 71.67

['Non-squamous Non-small Cell Lung Ca.. 2 0.21 71.87

['Osteoporosis', 'Postmenopausal Oste.. 2 0.21 72.08

['Pancreatic Cancer'] 2 0.21 72.29

['Pneumococcal Infections'] 2 0.21 72.50

['Pneumonia'] 2 0.21 72.71

['Prevention & Control'] 2 0.21 72.92

['Progressive Supranuclear Palsy'] 2 0.21 73.12

['Pseudomonas Aeruginosa Pneumonia'] 2 0.21 73.33

['Pseudomonas Aeruginosa'] 2 0.21 73.54

['Pulmonary Embolism'] 2 0.21 73.75

['Pulmonary Fibrosis'] 2 0.21 73.96

['Recurrent and/or Metastatic Head an.. 2 0.21 74.17

['Relapsed Multiple Myeloma', 'Refrac.. 2 0.21 74.37

['Relapsing Remitting Multiple Sclero.. 2 0.21 74.58

['Respiratory Distress Syndrome, Adul.. 2 0.21 74.79

['Schizophrenia'] 2 0.21 75.00

['Spinal Muscular Atrophy'] 2 0.21 75.21

['Staphylococcal Skin Infection'] 2 0.21 75.42

['Staphylococcus Aureus', 'Bacteremia.. 2 0.21 75.62

['Supranuclear Palsy, Progressive'] 2 0.21 75.83

['Surgical Procedures'] 2 0.21 76.04

['Thromboembolism'] 2 0.21 76.25

['Transcatheter Aortic Valve Replacem.. 2 0.21 76.46

['Transthyretin (TTR) Amyloid Cardiom.. 2 0.21 76.67

['Type 2 Diabetes Mellitus', 'Chronic.. 2 0.21 76.87

['Type 2 Diabetes'] 2 0.21 77.08

['Urothelial Cancer'] 2 0.21 77.29

['Venous Thromboembolism (VTE)'] 2 0.21 77.50

['Venous Thrombosis', 'Pulmonary Embo.. 2 0.21 77.71

['Ventilator-Associated Pneumonia'] 2 0.21 77.92

["Crohn's Disease", 'Colitis', 'IBD',.. 1 0.10 78.02

["Parkinson's Disease"] 1 0.10 78.12

['ASCVD', 'Elevated Cholesterol'] 1 0.10 78.23

['Acute Kidney Injury (AKI)'] 1 0.10 78.33

['Acute Myeloid Leukemia (AML)'] 1 0.10 78.44

['Acute Myeloid Leukemia'] 1 0.10 78.54

['Advanced Non-Small Cell Lung Cancer'] 1 0.10 78.65

['Advanced Renal Cell Carcinoma', 'Me.. 1 0.10 78.75

['Advanced or Metastatic (Medically o.. 1 0.10 78.85

['Age-Related Macular Degeneration'] 1 0.10 78.96

['Alzheimer Disease'] 1 0.10 79.06

['Amnestic Mild Cognitive Impairment'.. 1 0.10 79.17

['Amyotrophic Lateral Sclerosis', 'Mo.. 1 0.10 79.27

['Anesthesia'] 1 0.10 79.37

['Anklyosing Spondylitis'] 1 0.10 79.48

['Ankylosing Spondyloarthritis'] 1 0.10 79.58

['Antifungal Prophylaxis of Invasive .. 1 0.10 79.69

['Arteriovenous Fistula'] 1 0.10 79.79

['Aspergillosis'] 1 0.10 79.90

['Atrial Fibrillation', 'Percutaneous.. 1 0.10 80.00

['Atrial Fibrillation', 'Vascular Ris.. 1 0.10 80.10

['Avian Influenza'] 1 0.10 80.21

['Bacterial Infections', 'Virus Disea.. 1 0.10 80.31

['Bacterial Pneumonia', 'Community-Ac.. 1 0.10 80.42

['Benign Prostatic Hyperplasia'] 1 0.10 80.52

['Bipolar Disorder'] 1 0.10 80.62

['Blood Coagulation Disorders', 'Acut.. 1 0.10 80.73

['Bloodloss', 'Surgical Procedures, O.. 1 0.10 80.83

['Bloodstream Infections (BSI) Due to.. 1 0.10 80.94

['Bone Metastases in Men With Hormone.. 1 0.10 81.04

['COPD', 'Chronic Obstructive Pulmona.. 1 0.10 81.15

['COPD'] 1 0.10 81.25

['Cancer', 'Head and Neck Cancer', 'O.. 1 0.10 81.35

['Candidiasis, Invasive'] 1 0.10 81.46

['Carcinoma, Hepatocellular'] 1 0.10 81.56

['Carcinoma, Non-Small Cell Lung'] 1 0.10 81.67

['Carcinoma, Non-Small-Cell Lung', 'A.. 1 0.10 81.77

['Carcinoma, Non-Squamous Non-Small C.. 1 0.10 81.87

['Cardiac Arrest'] 1 0.10 81.98

['Cardiac Surgery Subjects', 'Subject.. 1 0.10 82.08

['Cardiovascular Diseases', 'Heart Di.. 1 0.10 82.19

['Castration-Resistant Prostate Cance.. 1 0.10 82.29

['Cerebrospinal Fluid Leaks'] 1 0.10 82.40

['Cervical Spinal Cord Injury'] 1 0.10 82.50

['Chemotherapy-Induced Nausea and Vom.. 1 0.10 82.60

['Chemotherapy-induced Neutropenia', .. 1 0.10 82.71

['Choroidal Neovascularization'] 1 0.10 82.81

['Chronic Heart Failure'] 1 0.10 82.92

['Chronic Kidney Disease', 'Secondary.. 1 0.10 83.02

['Chronic Lymphocytic Leukemia', 'Sma.. 1 0.10 83.13

['Chronic Lymphocytic Leukemia'] 1 0.10 83.23

['Chronic Renal Failure', 'Chronic Ki.. 1 0.10 83.33

['Chronic Troublesome Sialorrhea', "P.. 1 0.10 83.44

['Clostridium Difficile', 'Clostridiu.. 1 0.10 83.54

['Colon Cancer', 'Colorectal Cancer',.. 1 0.10 83.65

['Complicated Intra-Abdominal Infecti.. 1 0.10 83.75

['Coronary Artery Disease', 'Atherosc.. 1 0.10 83.85

['Cough', 'Sore Throat', 'Nasal Conge.. 1 0.10 83.96

['Current or Recent History of Atrial.. 1 0.10 84.06

['Cystic Fibrosis', 'Burkholderia Inf.. 1 0.10 84.17

['Deep Vein Thrombosis', 'Pulmonary E.. 1 0.10 84.27

['Delayed Graft Function'] 1 0.10 84.38

['Dementia, Alzheimer Type'] 1 0.10 84.48

['Diabetes Mellitus', 'Diabetes Melli.. 1 0.10 84.58

['Diabetes Mellitus, Type 2', 'End-St.. 1 0.10 84.69

['Diabetic Neuropathy, Painful'] 1 0.10 84.79

['Diabetic Retinopathy', 'Diabetic Ma.. 1 0.10 84.90

['Diffuse Large B-cell Lymphoma'] 1 0.10 85.00

['ESRD', 'Diabetes', 'CAPD', 'APD'] 1 0.10 85.10

['ESRD', 'Diabetes'] 1 0.10 85.21

['Elevated Cardiac Risk', 'Coronary A.. 1 0.10 85.31

['Eligible Men or Women Considered Hi.. 1 0.10 85.42

['End Stage Renal Disease (ESRD)', 'C.. 1 0.10 85.52

['End Stage Renal Disease (ESRD)', 'D.. 1 0.10 85.63

['End Stage Renal Disease', 'Anemia'] 1 0.10 85.73

['End-Stage Renal Disease (ESRD)'] 1 0.10 85.83

['Endometrial Cancer'] 1 0.10 85.94

['Epilepsy', 'Partial Epilepsy'] 1 0.10 86.04

['Esophageal Carcinoma', 'Esophagogas.. 1 0.10 86.15

['Esophageal Neoplasms'] 1 0.10 86.25

['Follicular Lymphoma'] 1 0.10 86.35

['Gastrointestinal Stromal Tumor (GIS.. 1 0.10 86.46

['Genital Neoplasms, Female', 'Fallop.. 1 0.10 86.56

['Geographic Atrophy'] 1 0.10 86.67

['Glioblastoma'] 1 0.10 86.77

['Gout'] 1 0.10 86.88

['HIV Infections', 'Lipodystrophy'] 1 0.10 86.98

['HIV Infections'] 1 0.10 87.08

['HIV-1 Infection'] 1 0.10 87.19

['HIV-1-infection'] 1 0.10 87.29

['Head and Neck Cancer', 'Squamous Ce.. 1 0.10 87.40

['Head and Neck Neoplasms', 'Carcinom.. 1 0.10 87.50

['Heart Failure', 'Coronary Artery Di.. 1 0.10 87.60

['Heart Failure', 'Type 2 Diabetes Me.. 1 0.10 87.71

['Hemostasis in Participants Receivin.. 1 0.10 87.81

['Hepatitis C', 'Hepatitis C, Chronic.. 1 0.10 87.92

['Hodgkin Lymphoma'] 1 0.10 88.02

['Homozygous Familial Hypercholestero.. 1 0.10 88.13

['Hormone Receptor Positive Breast Ca.. 1 0.10 88.23

['Hormone Receptor Positive Breast Ca.. 1 0.10 88.33

['Hormone Refractory Prostate Cancer'.. 1 0.10 88.44

['Hormone Refractory Prostate Cancer'] 1 0.10 88.54

['Hyperlipidemia'] 1 0.10 88.65

['Hyperlipidemias'] 1 0.10 88.75

['Hyperparathyroidism, Secondary'] 1 0.10 88.85

['Hypertension'] 1 0.10 88.96

['Infections, Papillomavirus'] 1 0.10 89.06

['Infertility'] 1 0.10 89.17

['Inflammation'] 1 0.10 89.27

['Influenza'] 1 0.10 89.38

['Influenza, Human'] 1 0.10 89.48

['Intermittent Preventive Treatment I.. 1 0.10 89.58

['Intraocular Lens Replacement'] 1 0.10 89.69

['Invasive Fungal Disease'] 1 0.10 89.79

['Iron Deficiency Anemia'] 1 0.10 89.90

['Kidney Failure, Chronic'] 1 0.10 90.00

['Kidney Transplantation', 'Graft Rej.. 1 0.10 90.10

['Leukemia, Acute Myeloid (AML)'] 1 0.10 90.21

['Leukemia, Myelogenous, Chronic, Bre.. 1 0.10 90.31

['Liver Transplant'] 1 0.10 90.42

['Liver Transplantation'] 1 0.10 90.52

['Low Back Pain'] 1 0.10 90.63

['Lung Cancer', 'Small Cell Lung Canc.. 1 0.10 90.73

['Lung Cancer'] 1 0.10 90.83

['Lung Cancer, Non-Small Cell'] 1 0.10 90.94

['Lymphoma', 'Multiple Myeloma'] 1 0.10 91.04

['Macular Edema (ME)'] 1 0.10 91.15

['Malignant Melanoma'] 1 0.10 91.25

['Melanoma', 'Metastases'] 1 0.10 91.35

['Mesothelioma', 'Lung Cancer'] 1 0.10 91.46

['Metastatic Breast Cancer'] 1 0.10 91.56

['Metastatic Non-small Cell Lung Canc.. 1 0.10 91.67

['Metastatic Renal Cell Carcinoma'] 1 0.10 91.77

['Metastatic Triple Negative Breast C.. 1 0.10 91.88

['Metastatic or Unresectable Cutaneou.. 1 0.10 91.98

['Mixed Hyperlipidemia'] 1 0.10 92.08

['Moderate Risk of CVD'] 1 0.10 92.19

['Mucositis', 'Solid Tumors', 'Stomat.. 1 0.10 92.29

['Multiple Sclerosis'] 1 0.10 92.40

['Multiple Sclerosis, Relapsing-Remit.. 1 0.10 92.50

['Multiple System Atrophy'] 1 0.10 92.60

['Myelodysplastic Syndrome'] 1 0.10 92.71

['Myelodysplastic Syndromes', 'Leukem.. 1 0.10 92.81

['NSCLC Stage IV'] 1 0.10 92.92

['Necrotizing Soft Tissue Infections'.. 1 0.10 93.02

['Neoplasm Metastasis', 'Colorectal C.. 1 0.10 93.13

['Neoplasms, Gastrointestinal Tract'] 1 0.10 93.23

['Neutropenic Complications', 'Breast.. 1 0.10 93.33

['Non Hodgkin Lymphoma'] 1 0.10 93.44

['Non Small Cell Lung Carcinoma NSCLC'] 1 0.10 93.54

['Non-Squamous Non-Small Cell Lung Ca.. 1 0.10 93.65

['Non-small Cell Lung Cancer', 'Lung .. 1 0.10 93.75

['Nonmetastatic Castration-Resistant .. 1 0.10 93.85

['Obesity', 'Type 2 Diabetes'] 1 0.10 93.96

['Opioid-Induced Constipation'] 1 0.10 94.06

['Osteoarthritis of the Knee'] 1 0.10 94.17

['Osteoarthritis', 'Arthritis'] 1 0.10 94.27

['Osteoarthritis, Hip', 'Osteoarthrit.. 1 0.10 94.38

['Osteoporosis in Men'] 1 0.10 94.48

['Osteoporosis', 'Osteopenia'] 1 0.10 94.58

['Ovarian Cancer'] 1 0.10 94.69

['Ovarian Neoplasms', 'Peritoneal Neo.. 1 0.10 94.79

['Palliative Care', 'Pain', 'Cancer'] 1 0.10 94.90

['Parkinson Disease'] 1 0.10 95.00

['Peripheral Arterial Disease'] 1 0.10 95.10

['Plaque Psoriasis'] 1 0.10 95.21

['Pneumonia, Bacterial'] 1 0.10 95.31

['Pneumonia, Pneumococcal', 'Pneumoco.. 1 0.10 95.42

['Pneumonia, Ventilator-Associated', .. 1 0.10 95.52

['Post-Operative Ileus (POI)'] 1 0.10 95.63

['Post-operative Nausea', 'Post-opera.. 1 0.10 95.73

['Postmenopausal Symptoms'] 1 0.10 95.83

['Postoperative Ileus'] 1 0.10 95.94

['Primary Progressive Multiple Sclero.. 1 0.10 96.04

['Primary Systemic (AL) Amyloidosis'] 1 0.10 96.15

['Psoriasis'] 1 0.10 96.25

['Recurrent Glioblastoma'] 1 0.10 96.35

['Relapsed/Refractory B-precursor Acu.. 1 0.10 96.46

['Relapsing-Remitting Multiple Sclero.. 1 0.10 96.56

['Renal Anemia, Chronic'] 1 0.10 96.67

['Renal Failure', 'Hemodialysis'] 1 0.10 96.77

['Respiratory Distress Syndrome, Newb.. 1 0.10 96.88

['Respiratory Syncytial Virus Infecti.. 1 0.10 96.98

['Retinopathy of Prematurity (ROP)'] 1 0.10 97.08

['Rheumatoid Arthritis (RA)'] 1 0.10 97.19

['Rotavirus Infections'] 1 0.10 97.29

['Sarcoma, Soft Tissue'] 1 0.10 97.40

['Sarcopenia'] 1 0.10 97.50

['Schistosomiasis'] 1 0.10 97.60

['Schizophrenia', 'Psychotic Disorder.. 1 0.10 97.71

['Severe Aortic Stenosis', 'Transcath.. 1 0.10 97.81

['Shingles'] 1 0.10 97.92

['Spinal Fusion Acquired', 'Spinal St.. 1 0.10 98.02

['Squamous Cell Carcinoma of Head and.. 1 0.10 98.13

['Squamous Cell Carcinoma of the Head.. 1 0.10 98.23

['Staphylococcus Aureus Bacteremia', .. 1 0.10 98.33

['Stents', 'Coronary Artery Disease',.. 1 0.10 98.44

['Stress Ulcer Prophylaxis'] 1 0.10 98.54

['Stroke', 'Secondary Prevention'] 1 0.10 98.65

['Tardive Dyskinesia'] 1 0.10 98.75

['Triple Negative Breast Cancer (TNBC.. 1 0.10 98.85

['Type 2 Diabetes Mellitus', 'Chronic.. 1 0.10 98.96

['Ulcer'] 1 0.10 99.06

['Unresectable Pleural or Peritoneal .. 1 0.10 99.17

['Unresectable or Metastatic Melanoma'] 1 0.10 99.27

['Unresectable, Recurrent, Locally Ad.. 1 0.10 99.38

['Urinary Tract Infections'] 1 0.10 99.48

['Vaccines, Pneumococcal'] 1 0.10 99.58

['Venous Leg Ulcer'] 1 0.10 99.69

['Venous Thromboembolism (VTE)', 'Dee.. 1 0.10 99.79

['Venous Thromboembolism', 'Deep Vein.. 1 0.10 99.90

['Wound Infection', 'Abscess', 'Syste.. 1 0.10 100.00

Total 960 100.00